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ABSTRACT
Kulczar, Christopher D. Ph.D., Purdue University, December 2016. The Development of
Preclinical Strategies for Facilitation of Lead Candidate Selection. Major Professor:
Gregory T. Knipp.

Chapter 1 details a background of techniques used for modeling the blood-brain
barrier (BBB). The BBB represents a diffusive barrier to both paracellular and
transcellular movement of many compounds in and out of the brain. The main ratelimiting barriers of the BBB include exclusive tight junctions that prevent the movement
of hydrophilic molecules through intercellular gaps, and efflux proteins in the membrane
which pump many hydrophobic molecules back into the blood. In addition, the BBB
contains metabolizing enzymes, including Cytochrome P450s. This barrier acts to protect
the vulnerable tissues of the brain from harmful xenobiotics, but also can serve as a
restrictive barrier for potential therapeutic compounds for the growing number of
neurological diseases, including Alzheimer’s disease, Parkinson’s disease, stroke,
depression, brain cancers, and many others. In fact, it is estimated that over 98% of
pharmaceutical compounds are unable to cross into the brain. Due to this problem, many
compounds must be screened in order to determine their BBB permeation and eventual
druggability. While in vivo testing in pre-clinical animals and humans is ideal for testing,
these methods aren’t suitable for early screening because of their high cost, low
throughput, and ethical considerations, especially in humans.
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Therefore, a number of in vitro cell screens have been established to mimic the
BBB for permeation testing. Principally, the best model should include primary human
brain microvessel endothelial cells (BMECs), however, due to the growing interest in
BBB permeation and lack of tissues, the supply is limited. As an alternative method,
many groups have investigated the use of primary animal BMECs, usually of murine,
porcine, or bovine source.

These models prove effective at restricting paracellular

movement; however, one must question the effects of animal isoforms on modeling
uptake, efflux, and metabolism of transcellular markers. This proves important as in vivo
most, if not all, therapeutic compounds will cross the BBB transellularly. Consequently,
much work has been done to establish immortalized human BMECs. These immortalized
cell lines alleviate the high cost and lack of supply found with primary human cells, but
potentially may serve as a better model for transcellular permeation over animal cell
lines. Currently, the most widely characterized immortalized human BMEC cell line is
the human cerebral microvessel endothelial cell line (hCMEC/D3). These cells express
tight junction proteins, efflux proteins, cyp450 enzymes, and are conducive to in vitro
testing. However, while these cells express tight junctions, their function is less than
ideal and leads to a leaky monolayer which may allow faster permeation through the
paracellular route or paracellular permeation of compounds that move transcellularly in
vivo leading to poor prediction of BBB permeability.

One method of investigating the

reason behind these leaky tight junctions was to take a closer look at the BBB itself.
Closer examination shows that while the endothelial cells of the BBB form the
main permeation barrier, these cells are surrounded by supporting cells such as astrocytes

xvi
and pericytes.

These cell lines are thought to promote proper differentiation of

endothelial cells in vivo, therefore, some groups have moved to co- and triculture models.
In these models, the supporting cells are plated on the basolateral side of a Transwell®
support and/or on the bottom of the well plate. After a given time, endothelial cells are
then plated on the apical side of the Transwell® and the cells are allowed to grow together
in the same medium. Due to the nature of the filter support, this allows crosstalk of
soluble factors between the endothelial cells and the supporting cells. In practice, this
often leads to decreased paracellular permeability and increased expression of tight
junction proteins. However, while having increased tightness, these models are still
leaky in comparison to in vivo conditions and even primary BMECs.
It is hypothesized that one reason for the continued lack of tightness may be due
the lack of direct contact between endothelial and supporting cells. While the Transwell®
filter support allows movement of soluble factors between the compartments, the distance
between cell layers is significantly higher than that found in vivo. This increased distance
may allow for increased dilution and degradation of soluble factors, reducing their
potency. In addition, the supporting cell lines are believed to secrete an extracellular
matrix (ECM) which also helps to promote differentiation. By splitting the cell lines with
the Transwell®, the endothelial cells are unable to interact with this secreted matrix.
Therefore, Chapters 2 and 3 discuss the optimization and establishment of a direct contact
coculture in vitro model in which both endothelial cells and astrocytes are plated on the
apical side of the Transwell® allowing for more physiologically relevant signaling
between the cells.

Early results suggest decreased paracellular permeation in this
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configuration compared to endothelial monocultures and indirect cocultures. In addition,
this setup should allow for easier transition to high-throughput equipment.
Additional studies in Chapter 4 attempt to show the utility of a new monoPEGylated Human Serum Albumin (HSA) as a potential enhancer of drug solubilization,
permeation, and eventual cytotoxicty. Multi-gram batches of short (5 kDa) and long (20
kDa) PEG-HSA were synthesized with high efficiency (77%) and characterized in
collaboration with Dr. Jonathan Mehtala and Dr. Alex Wei in the Department of
Chemistry.

Furthermore, effects of PEG-HSA on permeation of paclitaxel through

peripheral and BBB in vitro cell models as well as changes in cytotoxicity against MCF-7
cells was investigated.
Finally, Chapter 5 includes an investigation into the characterization, formulation,
and in vitro/in vivo testing of a potent V-ATPase inhibitor known as Saliphenylhalamide.
The V-ATPase is an endogenous protein that is responsible for acidifying intercellular
compartments and has been targeted in the past with in vitro success for treatment of
cancer and osteoporosis among other diseases. However, here we investigate its use as
an anti-viral therapeutic as acidification of endosomes by the V-ATPase is thought to be a
critical step in replication of alpha viruses. Initial characterization showed poor water
solubility and acid liability. Therefore, two solubility enabling formulations were created
and tested for in vitro permeability and in vivo murine pharmacokinetics.
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CHAPTER 1. MODELING THE BLOOD-BRAIN BARRIER

1.1

The Blood-Brain Barrier
The blood-brain barrier (BBB) is an active barrier, which selectively controls

molecular and cellular movement between peripheral blood flow and the brain.1 While
preventing the movement of harmful xenobiotics from entering the brain, it also allows
for selective uptake of endogenous substrates needed for optimal neuronal activity.2
Integrity of the BBB is necessary for proper neuronal function and disruption of the
barrier is very often associated with CNS-related diseases such as Alzheimer’s,
Parkinson’s, epilepsy, schizophrenia, as well as many others.3 While proper maintenance
and upkeep of the BBB is important for healthy living, the BBB also presents a major
obstruction to delivery of pharmaceutical compounds to treat neurological and
neurodegenerative disorders.4
The BBB’s effectiveness in excluding xenobiotics is often attributed to the brain
microvessel endothelial cells (BMECs) that form the capillaries of the brain.5 These
endothelial cells are significantly restrictive to both paracellular permeation of
hydrophilic molecules, through the formation of exclusive tight junctions, and
transcellular diffusion of hydrophobic molecules, through the presence of luminal efflux
proteins and intracellular metabolizing enzymes.6 However, while they represent the ratelimiting permeation step, histological analysis shows the presence of other cells at the
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BBB, including astrocytes, pericytes, neurons, and microglia. Further investigation into
these cells has shown their importance in BBB development and upkeep. Due to the
cohesive nature of these cells, the group was termed the neurovascular unit.7

1.2

The Neurovascular Unit
A cross-section of the BBB shows the coordination of the neurovascular unit and

can be seen in Figure 1.1. As noted, the initial and rate-limiting barrier in blood-to-brain
permeation is the endothelial cells. These cells, however, are wrapped in supporting cells
which are thought to be the differentiating factor between BMECs and endothelial cells
of the periphery.8 This was confirmed through in vivo animal experiments showing that
growing brain grafts in the periphery lead to decreased paracellular tightness, while
grafting peripheral tissues into the brain induced tightening of the endothelium.9 Here we
look further into the roles of both the endothelial cells as well as some of the supporting
cells of the neurovascular unit.

3

Figure 1.1. The Cellular Associations of Neurovascular Unit. Modified From Abbott NJ,
et al. 2010.10

Endothelial Cells
The endothelial cells that form the capillaries of the BBB are different from those
in the periphery in a number of ways. The first, as mentioned above, is a reduced
paracellular permeability due to the presence of specialized tight junctions.11 In addition,
the endothelium of the BBB is continuous and lacks fenestrations which further limits
paracellular permeability.12 Permeability of even large hydrophobic molecules is
restricted in comparison to the periphery due to reduction in both transcytosis and
pinocytosis.13

The BMECs also contain a high number of energy-producing

mitochondria in comparison to the periphery which allows for increased metabolism and
transport.14 Finally, endothelial cells contain a higher density of nutrient, i.e. glucose and
amino acid, and efflux transporters, i.e. p-glycoprotein, which allows for increased

4
selectivity of transcellular permeability.15 While these characteristics distinguish the
BBB from the periphery, the manifestation of these properties is determined by
interactions of the supporting cells of the neurovascular unit as discussed below.

Astrocytes
As mentioned above, the properties of BMECs are not intrinsic to the cells, but
brought on through induction in the CNS environment.16 This induction is in part thought
to be due to BMEC-astrocyte intercellular signaling. This hypothesis was confirmed
through early in vitro studies which showed BBB-like differentiation in astrocyteconditioned media.17 This media is partially spent media in which astrocytes are
temporarily grown in and contains soluble factors secreted by the astrocytes.

This

suggests that paracrine signaling by the astrocytes is likely to be important. However,
further studies showed that additional BBB induction, i.e. decreased paracellular
permeability and increased tight junction protein expression, was seen when astrocytes
and BMECs were grown together separated by a filter support.18,19

This possibly

suggests cross-talk between the astrocytes and BMECs is necessary for physiologicallyrelevant BMEC differentiation.
A number of studies have been conducted to delineate the agents which lead to
astrocyte-induced BBB differentiation and maintenance.
pathways can be seen in Figure 1.2.

Some of these signaling

5

Figure 1.2. BMEC-Astrocyte Cell-Cell Signaling. LIF- Leukemia Inhibitory Factor,
TGFβ-Transforming Growth Factor-β, bFGF- Basic Fibroblast Growth Factor, ANG1Angiopoetin 1, GDNF- Glial-Derived Neurotrophic Factor, ET- Endothelin 1, TIE2Endothelium Specific Receptor Tyrosine Kinase 2, P2Y2- Purinergic Receptor, and 5HT- Serotonin . Modified From Abbott NJ, 2006.20

As can be seen in the figure, signaling occurs in both directions with astrocytes
inducing BMECs through soluble factors such as basic fibroblast growth factor (bFGF)
and vice versa with factors such as leukemia inhibitory factor (LIF) which is released by
the endothelial cells to promote astrocyte differentiation. While the importance and
function of these factors is under some debate, addition and removal of these markers in
in vitro cell models leads to significant changes in physiological relevance.18,20,21
It should also be noted that astrocytes are glial cells with a star-shaped
morphology. This star shape is formed by the outgrowth of a number of processes which
end at a portion of the cell known as the astrocyte end foot. These end feet wrap
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endothelial cells, covering almost the entirety of the capillaries basolateral surface area
creating a large surface area in close contact.22 This may suggest that close interactions
between the astrocytes and BMECs is important, and is the basis for the chapters 2 and 3.

Pericytes
Early investigations of the BBB suggested that while other cell types were found
in the neurovascular unit, the main cell line responsible for BBB induction was the
astrocytes.23 However, recent in vitro studies suggest that the pericytes may also play a
role as BMECs grown in coculture with pericytes sometimes show increased TEER
values which are indicative of BBB induction.24 Interestingly, pericyte coverage is not
uniform throughout the BBB and varies from approximately 30-100% depending on the
location in the brain. This may suggest varying roles throughout the brain.25
Unfortunately, little is known about pericyte and endothelial cell interactions,
though their close interaction suggests that pericytes may be important for the BBB
phenotype. Interestingly, pericytes are found throughout the vasculature and are thought
to be important for structural stability and microcontrol of capillary blood flow.26 They
also appear to play a role in regulation of BBB angiogenesis. In addition, recent
investigation shows that the pericytes may produce much of the extracellular matrix
responsible for supporting cell-cell interactions in the BBB as pericytes are known to
secrete collagen, laminin, fibronectin, and glycosaminoglycans.27
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Extracellular Matrix
As it is not a cell-line and therefore not involved in active signaling, the
extracellular matrix (ECM), also known as the basement membrane or basal lamina, is
often thought of as a passive player in BBB differentiation. However, the ECM serves as
important site for adhesion of the cells of the neurovascular unit, keeping them in close
contact.28 It also may be important for promotion of cell polarity.29 The ECM of the
BBB varies in thickness and is thinner than that of the periphery ranging from 20-200
nm.30 It consists of entwined protein sheets comprised of mainly collagen (mostly Type
IV which is indicative of the BBB), laminins, nidogens, heparin sulfate proteoglycans
(i.e. agrin).31 Interestingly, each of these proteins is mostly excreted by different cell
lines, which suggests that interaction between different cells in the neurovascular unit
may be important.32
Support for the importance of the ECM at the BBB can be seen in a number of
disease states.

For instance, tumors of the brain are often absent of the astrocyte-

produced agrin.20 This is thought to play a part in the increased leakiness found in the
vasculature feeding these tumors. In addition, genetic mutations in Type IV collagen
leads to brain hemorrhage in animal models.33 While this suggests that the ECM is
important, the exact functions are still unknown.

One method of studying these

interactions is through in vitro cell culture, however, the ECM used in these cultures is
often much simpler than the complex matrix found in vivo. This makes it difficult to
draw conclusions, and also may represent a deficiency in in vitro BBB cell models.
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1.3

Permeability Barriers of the Blood-Brain Barrier
As stressed above, the main feature of the BBB is its ability to act as a highly

selective barrier to permeation into the brain.

This helps to protect the vulnerable

neurons, while allowing permeation of nutrients needed for proper brain function.6 While
nutrient uptake transporters are physiologically important and may be taken advantage of
for drug delivery, this section will focus on barriers.

These barriers include, tight

junctions which are responsible for preventing paracellular permeation of hydrophilic
molecules, efflux transporters which pump hydrophobic molecules back into the blood
preventing transcellular permeability, and drug metabolizing enzymes (DMEs) which act
to break down and inactivate potentially harmful xenobiotics that manage to enter the cell
cytoplasm.34 Potential routes of permeation are shown in Figure 1.3 below.

Figure 1.3. Routes of Permeation Across the Blood-Brain Barrier. Modified from Knipp
GT, Unpublished.
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Tight Junctions
Tight junctions are protein assemblies which form complex intramembranous
strands.11 Complementary strands on neighboring cells interact through protein-protein
interactions of integral membrane proteins, closing the gap between the cells.35 While
found in other areas of the body including the kidney and intestine, the tight junctions of
the BBB are the most exclusive and most abundant.5 In the brain, these tight junctions
are known to exclude even small elemental ions such as Na+ and Cl-. This restriction of
ions leads to high in vivo transendothelial electrical resistance (TEER) of 1,500-2,000
Ω*cm.2,20 This high electrical resistance is indicative of the BBB phenotype, and is often
used as a marker for distinguishing BBB induction. The main function of the tight
junctions is to prevent the movement of hydrophilic molecules by the paracellular route
through cell-cell junctions.36 In addition, the tight junctions also promote cell polarity by
preventing the diffusion of transmembrane proteins expressed on the apical and
basolateral surfaces of the cell.37
The tight junctions are highly regulated and organized being composed of a
complex interaction of both integral membrane proteins, i.e. occludin, claudins, and
junctional adhesion molecules (JAMs), and intercellular accessory proteins , i.e. zona
occludins (ZO) and cingulin, which can be seen in Figure 1.4.11 As mentioned above, the
integral membrane proteins act as extracellular sites for cell-cell interactions, however,
these proteins must be connected to the cytoskeleton by the cytoplasmic accessory
proteins to allow for the contraction responsible for closing cell-cell gaps.28
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Figure 1.4. Molecular Organization of the Tight Junctions. Modified From Neuwelt, et
al. 200838

Within the tight junction, different proteins are believed to have different roles.
Claudins are believed to be the main protein responsible for sealing the tight junction
through homo- or heterotypic binding.39

While well over 20 claudins are known,

claudin-1, claudin-3, and particularly claudin-5 are thought to be responsible for the
increased tightness found in the brain.11,39 Occludin proteins were once thought to be the
main permeation barrier, however, knockout studies have shown only small changes in
paracellular permeability in vivo, which are not indicative of a phenotype devoid of tight
junctions.40 Instead, it is now thought that changes in occludin phosphorylation state may
be important for regulating small changes in tight junction permeability.11 While not
playing a physical role in actual permeability restriction, the intracellular accessory
proteins are important for tight junction localization, formation, and function. In fact,
loss of ZO-1 and ZO-2 leads to loss of claudin recruitment and failure to form tight
junctions.40
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Drug Efflux
While the tight junctions prevent paracellular permeation at the cell junction, the
BBB is also impermeable to many hydrophobic molecules which must often transverse
the barrier through passive transcellular permeation.3 In large part, this impermeability is
due the dense presence of energy dependent ATP Binding Cassette (ABC) transporters
known as efflux transporters shown in Figure 1.5. These transporters use ATP to pump
molecules out of the cell against their concentration gradients.41 The transporters are
comparatively unspecific in comparison to their uptake counterparts, and act to pump a
variety of different compounds. In addition, they have a large overlap of substrates
leading to reduced permeation of many compounds even if one efflux transporter is
absent or knocked down.42 It is likely that these transporters evolved to prevent harmful
toxins and xenobiotics from reaching the brain, however, these proteins now present a
significant barrier to drug delivery.43
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Figure 1.5. Efflux Proteins at the Blood-Brain Barrier. Modified From Löscher. 2005.41
Looking at Figure 1.5, it is interesting to see that while a number of the most
commonly cited efflux proteins such as P-glycoprotein (P-gp), breast cancer resistance
protein (BCRP), and some multidrug resistance proteins (MRPs) are found on the luminal
membrane of the endothelial cells, additional transporters are found on the abluminal
surface facing the brain.41 This is likely to pump endogenous neurotrophic factors against
their concentrations and kept within the brain.44 While these abluminal transporters may
serve as a potential area for drug delivery exploitation, through both increased
permeation across the endothelial barrier and reduced clearance from the brain, little
investigation in this area appears in the literature. Instead, most research is focused on
overcoming luminal efflux.
In general, the more hydrophobic the molecule the more readily it permeates the
BBB as can be seen in Figure 1.6. However, as mentioned above, the efflux proteins of
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the BBB are notoriously promiscuous and in addition, many of these transporters are
upregulated in various disease states.45

As indicated in the figure, while BBB

permeability increases with the partition coefficient, so does the likelihood of being a
substrate for efflux transporters.46 This further complicates drug development making
early prediction through in silico and in vitro modeling imperative.

Figure 1.6. Blood-Brain Barrier Permeability vs. Partition Coefficient. Dark Colored
Ovals Reflect Efflux and Uptake Markers. Modified From Begley, D. 2004.46

Drug Metabolizing Enzymes
Drug metabolizing enzymes are a class of enzymes known to modify
pharmaceutical compounds in a number of ways often leading to increased clearance and
reduced potency. Drug metabolism is broken up into two categories known as Phase I
and II.

Phase I metabolism (including oxidation, reduction, or hydrolysis) acts to

introduce reactive/polar constituents into their substrates which often leads to increased
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elimination.47 Phase II metabolism, on the other hand, utilizes molecular conjugation
(i.e. methylation, acetylation, glucuronidation, etc) as opposed to molecular
modification.48 Oftentimes, these routes of metabolism are used in conjunction with a
site for Phase II conjugation being first formed through Phase I molecular modification.47
As can be seen in Figure 1.7, even if pharmaceutical compounds are able to
permeate into the cell, a number of DMEs are present to potentially degrade them.
Interestingly, expression of DMEs at the BBB is significantly different at the microvessel
than in the cortex which may be due in part to the differences in endogenous
metabolomic needs.49 In addition, while CYP3A4 is generally first thought of due to its
high expression in the periphery, some suggest little expression is seen in the brain.
Instead, high amounts of CYP1B1 are found compared to the periphery.34 It should also
be noted, that in addition to BMECs, astrocytes are also thought to produce CYPs, though
in vivo expression patterns aren’t well understood.
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+
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ND
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CYP2C9
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ND
CYP2C18
ND
ND
CYP2C19
ND
ND
CYP2D6
+
+
CYP2E1
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ND
ND
CYP3A5
ND
ND
CYP3A7
ND
ND
Transcription Factors
PXR
ND
ND
CAR
NQ
NQ
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+
+

Figure 1.7. In Vivo mRNA Expression of Human Drug Metabolizing Enzymes at the BBB.
ND-Not Detected,

NQ-Non-Quantifiable. Results are from 7 patients. Modified From

Dauchy, et. al. 2008.49

1.4

In Vitro Models of the Blood Brain Barrier
Ideally, one would use in vivo animal models to predict disposition into the brain

due the complexity of the BBB.

A number of techniques are available including

intravenous injection, injection into the carotid artery, perfusion studies, and intracerebral
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microdialysis.50,51 While these techniques are highly invasive and only possible in
diseased patients and animal models, sampling of human cerebral spinal fluid (CSF) is
possible for compounds which have reached clinical trials. However, the correlation
between disposition into the brain and CSF is debatable.52 Nonetheless, all of these
studies are rather expensive and unrealistic especially for drug discovery and lead
selection. Therefore, in silico and in vitro models have been established to, at minimum,
help rank order druggable candidates in discovery.
The simplest in vitro BBB models consist of cerebral microvessels in
monoculture.

In these models, BMECs are plated onto microporous inserts, i.e.

Transwell® filter supports.53 While human BMECs would be ideal, models often utilize
primary cells of various animal origins including bovine, porcine, murine, rat, and
monkey due to the high demand and low availability of human tissues.34 While these
cells are often cheaper and easier to acquire, it is important to recognize potential species
differences, which affect all routes of permeation. For instance, many animal endothelial
cells express over two-fold increases in claudin-5 as compared to human BMECs.54 In
addition, many species express varying levels of efflux transporters, often with much
higher P-glycoprotein expression and lower levels of BCRP and MRPs.55

Finally,

expression differences in DMEs are speculated to be highly variable between species.56
These changes can culminate in significant changes in BBB permeability prediction as
shown in a recent study comparing rodent and human BBB models which predicted, on
average, two-fold higher permeability in rodent models for a small catalog of
compounds.57
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In order to alleviate some of these issues, a number of groups have begun work in
immortalization of human BMECs. Immortalization of these cells allows for a more
consistent phenotype over a longer number of passages, drastically increasing supply. A
few immortalized human BMEC cell lines are currently available including human
cerebral microvessel endothelial cells (hCMEC/D3s), human brain microvessel
endothelial cells (hBMEC), TY10 cells, BB19 cells, as well as a number of proprietary
cell lines.58 However, all of these cell lines suffer from one significant detriment in an
inability to prevent paracellular permeation, a hallmark of the BBB.58 Immortalized cell
lines often suffer from low TEER which rarely reaches 150 Ohm*cm2, much lower than
reported in vivo values (though it should be noted that these in vivo values are reported
from animal specimens).34,59 In an attempt to increase TEER, some progress has been
made through media optimization, different immortalization techniques, and primary cell
culture selection; however, the largest increases have been seen through coculture with
supporting cells of the neurovascular unit.8,16-18,24,53,57,60-65
Since it is believed that interactions between BMECs and supporting cells of the
neurovascular unit are at least in part responsible for the BBB endothelial cell phenotype,
it is somewhat unsurprising that lack of this interaction leads to poor in vitro relevance.
As discussed above, while first studied to examine the role of supporting cells at the
BBB, coculture with these cells has lead to increased tight junction complexity and
function as well as upregulation of a number of transporters.16,20,21 For this reason, many
studies now utilize co- and triculture in in vitro BBB permeability prediction. A number
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of setups have been reported including culture with astrocytes, pericytes, and/or neurons.
Some of these models are shown in Figure 1.8.

Figure 1.8. In Vitro Transwell Co- and Triculture Models. Cells are represented as
Blue-Endothelial Cells, Purple-Pericytes, and Green-Astrocytes.
While results have been somewhat inconsistent, all of these models have been
shown to lead to varying degrees of increased TEER. However, while TEER has
increased, only small changes in marker paracellular permeability were seen and still
represent a drastically less restrictive model in comparison to in vivo conditions.34 An
additional downside to these models is in increased complexity in cell culture which may
hinder their utility in high-throughput screens. This is especially true of the models
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which utilize culturing cells on the underside of the Transwell® support. In order to
culture in this fashion, the filter is first flipped and cells are allowed to adhere and
proliferate for a designated amount of time.62 This process is likely to be a very difficult
accomplishment by automated high-throughput cell culture technologies.
Due to the continued lack of adequate tight junctions in the Transwell® model, a
few new models have been developed. One of these models was coined the dynamic in
vitro model.66 Here a hollow porous fiber is used instead of a flat filter. Endothelial cells
are seeded onto the inside of this fiber and in some cases supporting cells are seeded onto
the outside. After adhesion, media is pumped through the model which allows for
continual shear on the cells similar to that found in vivo.67 Interestingly, while further
investigation is needed, hCMEC/D3 TEER approaches 1000 Ω*cm2 suggesting that shear
may play a crucial role in BMEC differentiation.68

Additionally, new microfluidic

models have been established which also utilize shear as a mechanism of
differentiation.69

In these models, a semi-porous filter is placed between two

microfluidic channels. The setup of these models is very similar to the Transwell®
models, with the exception that media is then pumped across these channels to mimic
shear. Due to the small size of these models, they also require a much lower number of
cells, which may allow them to be conducive to studies with primary human cells.69
Although it is an interesting model, at this time TEER values in these microfluidic
models are still comparable to Transwell® models.
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CHAPTER 2. INNOVATION AND OPTIMIZATION OF A DIRECT
CONTACT BLOOD-BRAIN BARRIER IN VITRO MODEL
2.1

Innovation of a Direct Contact Coculture In Vitro Model

Cell Selection
Cell selection first began with selection of an endothelial cell line. While it is
believed that primary human BMEC’s may represent the most physiologically relevant
cell line for the model, at this time they are cost prohibitive due to their low supply and
high demand. Therefore, an immortalized human BMEC line was selected.1 Because of
its history in our lab and popularity in the field, the human cerebral microvessel
endothelial cell line (hCMEC/D3) was selected as the endothelial cell line for initial
studies.
The hCMEC/D3 cell line was developed and graciously donated by Dr. Pierre
Couraud of the Universite Rene Descartes. The primary cell line was isolated from
excised tissue of an adult female with epilepsy and then immortalized through lentiviral
transduction of hTERT and SV40 large T-antigen.2 These proteins act in conjunction to
prevent reduction in telomere length which acts to extend the useful number of passages
for a cell line. The hCMEC/D3s are known to grow for at least 35 passages without
exhibiting dedifferentiation or senescence, which represents a large increase in useful
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lifespan over primary cells which often last less than 5 passages.3 In addition,
hCMEC/D3 cells are contact-inhibited meaning that upon cell-cell contact the cells move
from a proliferative state to a differentiated state. This makes them a good candidate for
monolayer formation in in vitro studies.2,3
In addition, the cell line also expresses most BBB-specific markers which are
important in cell screening of pharmaceutical compounds across the BBB.3 hCMEC/D3s
express tight junction proteins such as ZO-1, JAM-A, occludin, as well as claudins,
including claudin-5 which is thought to be the most important for BBB tightness.4 They
are also known to express a number of efflux proteins including P-glycoprotein, MRP1,
and BCRP.5 Finally, previous work in our lab has shown expression of a number of ABC
and SLC transporters.6

However, while all of these proteins are expressed, their

expression in hCMEC/D3s varies widely when compared to primary human BMECs.7 In
addition, at least when grown in monoculture, localization at cell-cell contacts of some
tight junction proteins is not seen which may indicate the reason for increased
paracellular permeation across hCMEC/D3 monolayers.
Due to the current lack of an established immortalized human astrocyte cell line,
primary human astrocytes were purchased from ScienCell. While a lack of supply and
high cost are disadvantages to using the primary human astrocytes, the use of a human
cell line was deemed necessary leaving few options at this time.

In addition, it’s

speculated that lot-to-lot differences in astrocytes would have reduced effects when
compared to endothelial cells due to their mostly supportive role in barrier formation.
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This is confirmed in part by insignificant differences between multiple cell lots currently
used in the lab.

Direct Contact Model
In order to initially test the hypothesis that direct-contact coculture of hCMEC/D3
and human astrocytes leads to a more physiologically relevant model, a preliminary study
was run to measure the differences in [C14]-Mannitol permeability between hCMEC/D3
cells alone in monoculture and in coculture with human astrocytes. Initial studies were
conducted on collagen coated Transwell® filter supports.

In order to maintain

physiological relevance, the human astrocytes were plated first at 40,000 cells/cm2 in
astrocyte medium. Astrocytes were allowed to proliferate to confluence which took
approximately two days. A confluent layer of astrocytes was used to allow maximum
contact between human astrocytes and hCMEC/D3s as well as to allow the hCMEC/D3s
to have an increased chance of forming their own confluent monolayer on a more even
surface. In addition, this time allows the astrocytes to produce their ECM which is
thought to enhance BBB differentiation. After human astrocytes reached confluence,
hCMEC/D3 cells were plated in supplemented EBM-2 at a density of 100,000 cells/cm2.
This density, up to two-fold higher than normally used, was selected as 100% attachment
to the astrocyte monolayer wasn’t expected. The hCMECs were then allowed 7 days to
proliferate and differentiate in contact with the human astrocytes before [C14]-Mannitol
permeability was measured. The hCMEC/D3 monocultures were grown in a similar
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fashion, onto collagen-coated Transwells® at a density of 100,000 cells/cm2 and allowed
to grow for 7 days before studies. The results of the initial study are shown below.

Apparent Permeability [x10-5 cm/s]
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Figure 2.1.

Coculture

Effect of Direct Astrocyte Coculture on hCMEC/D3 [C14]-Mannitol

Permeability. Data is means ± 1 standard deviation of N=3 studies. **:p<0.05

As can be seen, a significant reduction in [C14]-Mannitol, a paracellular marker,
was measured when growing hCMEC/D3 cells in coculture with human astrocytes versus
monoculture. Given that one of the significant limitations of hCMEC/D3 monolayers lies
in their inability to prevent paracellular permeation, this preliminary study suggests that
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direct-contact coculture may serve as a more physiologically-relevant model for in vitro
BBB permeability prediction.

2.2

Optimization
While initial studies were promising, additional optimization was conducted.

Optimization of in vitro models is often extensive as many factors play a role in protein
expression and cell function. While not an exhaustive optimization, the following studies
elucidate parameters that may have the most influence. Since the greatest drawback to
the hCMEC/D3 cell line is its high paracellular permeability, optimization was focused
on reducing permeability of the paracellular markers [C-14]-Mannitol and [C14]-Sucrose.

Seeding Density
Seeding density represents the number of cells per area plated on the Transwell®
permeable support and is given in the units of cells/cm2. Seeding density serves as an
important parameter, especially for contact inhibited cell lines like the hCMEC/D3s.
Overseeding at a high density can lead to overgrowth, monolayer doming, and multilayer formation which reduce the formation of tight junctions.

On the other hand,

underseeding contact-inhibited cells can lead to colony-like growth due to high amounts
of localized cell-cell contact before confluence is reached. A broad range of densities for
both hCMEC/D3s (50-100,000 cells/cm2) and human astrocytes (10-40,000 cells/cm2)
were tested. Results are shown below:
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Figure 2.2.

Effect of Human Astrocyte and hCMEC/D3 Cell Densities on [C14]-

Mannitol Permeability. Key is represented as hCMEC/D3 density x1000 followed by
human astrocyte density x1000). Data is means ± 1 standard deviation of N=3 studies.

As can be seen, initial studies suggest that at least in monoculture, higher
hCMEC/D3 cell densities lead to lower permeability. It should be noted that 250,000
cells/cm2 was also run, however, the cell monolayers began to roll making them unable to
be used for permeability testing. Interestingly, however, at least in the large range of
densities measured, neither the hCMEC/D3 or human astrocyte density seems to play a
significant role under current culturing conditions. In addition, no trends were seen that
would suggest that the ratio of hCMEC/D3 to human astrocytes is significant in our
model.
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Seeding Time
In this case, seeding time represents the number of days the cells are allowed to
grow post-hCMEC/D3 seeding. Seeding time is often useful in determining both the
optimal and acceptable range of days to conduct permeation studies. If studies are done
too quickly, the cells do not have adequate time to reach confluence, differentiate, and
express tight junction proteins, efflux transporters, etc. However, if the cells are grown
for too long, the cells begin to go through apoptosis and monolayer integrity is lost.
Also, these additional culture days represent an increase in both cost and time which
hinder the utility of a model. Previous work in our lab suggests that the best day for
culturing hCMEC/D3 monocultures is approximately 14 days. For this reason we chose
to center around this time and measure permeation every other day from day 5 to day 19.
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Figure 2.3. Effect of Seeding Time on [C14]-Mannitol Permeability. Data is means ± 1
standard deviation of N=3 studies.

Interestingly, over the time course of the studies run from day 5-19, seeding time
seemed to show little significance on [C14]-Mannitol permeability.

The highest

permeability was on day 5, which suggests that full confluence and differentiation still
isn’t reached at this time. However, neither significant differences nor trends were seen
from day 7 to day 19.

This suggests that the hCMEC/D3 monolayers reach full

confluence and tight junction differentiation by day 7 and are viable at least until day 19.
While for our purposes day 7 appears to be the best day for studies in terms of cost, time,
and money, it should be noted that only paracellular permeability has been measured at
this time.

Additional culture time may be required for full differentiation and
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physiologically relevant protein expression and function. Further studies need to be
conducted to elucidate these changes in protein expression over time, however, these
studies are currently cost-prohibitive.

Seeding Order
In order to determine if a confluent astrocyte monolayer was necessary for
hCMEC/D3 monolayer formation, both hCMEC/D3 cells and human astrocytes were
plated concurrently. In these studies, hCMEC/D3s and human astrocytes were plated
together at 100,000 and 40,000 cells/cm2 together on collagen coated Transwells® and
compared to studies conducted as described in section 2.1.2. Results of the study are
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As expected, it is apparent from this study that concurrent plating of human
astrocytes and hCMEC/D3’s significantly disrupts the ability of the hCMEC/D3s to form
a monolayer and establish cellular tight junctions. This is likely due to a purely physical
or steric interaction with the human astrocytes blocking the ability of neighboring
hCMEC/D3 cells to establish cell-cell contact. While concurrent plating doesn’t appear
to be ideal, additional studies could be conducted to establish the optimal of time to seed
hCMEC/D3 cells after human astrocyte plating.

Basement Membrane Selection
The basement membrane protein(s) used in a cell culture system are often used as
a means to keep a cell monolayer flat for in vitro studies. Frequently, endothelial cells
will roll into a capillary-like formation upon differentiation due to the poor adhesion
between endothelial cells and cell culture plastics. This prevents their use in Transwell®
based permeability studies due to the lack of a monolayer and a defined direction of
membrane polarization. To counteract this, a basement membrane protein is first seeded
down onto the Transwell® and given time to adhere to the plastic. After which, the cell
line is placed onto of this ECM layer which acts as a “glue” between the cell line and the
plastic.
However, while the basement membrane protein is often chosen solely on its
ability to stabilize a cell monolayer, it is known that the ECM is important for cell
proliferation and differentiation.8

Therefore, four different membrane proteins were
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tested including Type I rat tail collagen, poly-L-lysine, fibronectin, and MaxGel to
measure their influence on tight junction formation. It should be noted that in vivo some
of the basement membrane proteins tested are found at low or zero levels. Consequently,
MaxGel, a proprietary ECM made by Sigma-Aldrich, was also selected as a more
relevant matrix. MaxGel contains a mixture of basement membrane proteins including
collagens, laminin, fibronectin, tenascin, elastin, proteoglycans, and glycoaminoglycans.
Due to the complex nature and closer composition to that found in vivo, MaxGel is often
used to help promote proliferation and differentiation in BBB cell lines.
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Figure 2.5.

Poly-L-Lysine
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Effect of Basement Membrane Protein Selection on

MaxGel

[C14]-Mannitol

Permeability. Data is means ± 1 standard deviation of N=3 studies.

While fibronectin was found to give a significantly higher permeability for [C14]Mannitol, the other three basement membrane proteins tested showed no significant
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differences.

However, seeding onto poly-L-lysine and Maxgel led to quantitatively

slower paracellular permeability. Due the high cost of MaxGel, and the difficulty in
working with it, poly-L-lysine was selected as the best choice for future studies. One may
question why such small changes were seen upon using different basement membrane
proteins, particularly in the case of MaxGel. It is hypothesized that this is due to the
nature of the direct coculture model. In this case, human astrocytes are plated onto the
basement membrane protein and then allowed to produce their own ECM in which the
hCMEC/D3 cells can adhere. As the hCMEC/D3 cells are the rate-limiting barrier in
paracellular permeation across the coculture model, a large change would only be
expected if the modification in basement membrane proteins caused an alteration in
astrocyte secretion of a matrix protein involved in BMEC differentiation.

Media Selection
Due to the nature of the direct contact coculture model containing two cell lines, it
is possible that differentiation and proliferation may occur better in one media over
another. The hCMEC/D3 cell line is grown in an endothelial basal medium (EBM-2)
base from Lonza Inc., while the human astrocytes are grown in a proprietary human
astrocyte medium (AM) sold with the primary cells by ScienCell. In practice, both cell
lines grow in both mediums, but in monoculture grow best in their perspective mediums.
For this reason, all coculture studies began with plating, proliferation, and differentiation
of astrocytes in astrocyte media for the first two days prior to hCMEC/D3 plating.
Following hCMEC/D3 plating, the cells were then either kept in astrocyte media for the
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remaining seven days or switched over to EBM-2 for the remaining seven days. In
addition, due to the nature of the Transwell®, it is also possible to add separate mediums
in the apical and basolateral compartment. This allowed for the investigation of EBM-2
on the apical side in contact with the hCMEC/D3 cells and astrocyte medium in the
basolateral side in closer contact to the human astrocytes.

Apparent Permeability [x10-5 cm/s]

2.5
**
2

1.5
*
1

0.5

0
EBM-2/EBM-2

AM/AM

EBM-2/AM

Figure 2.6. Effect of Base Medium on [C14]-Mannitol Permeability Across the Direct
Contact Coculture Model. Data is means ± 1 standard deviation of N=3 studies. *:
p<0.05 **:p<0.01

Figure 2.6 shows that the coculture model grown with EBM-2 in both
compartments leads to the lowest paracellular permeation of [C14]-Mannitol.

The

combination of EBM-2 in the apical compartment and astrocyte medium in the
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basolateral compartment was significantly less restrictive than EBM-2 in both
compartments, however, both were much tighter than the coculture grown in just
astrocyte medium. This isn’t unexpected as the hCMEC/D3 cell line is the rate limiting
barrier in the model and grows best in EBM-2. In addition, the majority of the
proliferation and differentiation of the human astrocytes is likely completed by the time
the media is switched to EBM-2. Further investigation would need to be completed to
elucidate the mechanism behind the differences between hCMEC/D3 differentiation in
EBM-2 vs. astrocyte medium, however, due to the proprietary formulas of each medium
investigation would be difficult.

Media Optimization
While EBM-2 in both the apical and basolateral compartments of the coculture
model was found to elicit the tightest paracellular barrier, further media modifications
may lead to further tightening. Previous unpublished work in our lab has shown that for
hCMEC/D3 monolayers, addition of different soluble factors, including growth factors,
metal ions, antioxidants, lipids, and buffers, leads to significant tightening. As the direct
mechanisms behind hCMEC/D3 monolayer tightening upon coculture with astrocytes are
unknown, further investigation was done to elucidate the effects of media modification
on the direct contact coculture model.
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Serum-Free Media
Serum is often used in cell culture as it contains a number of factors important for
cell growth and proliferation.9 Its use is often needed not only for initial growth, but also
to prevent senescence or apoptosis even after differentiation of some cell lines. However,
studies using primary porcine BMECs have found that removal of serum during cell
culture led to a two-fold increase in transendothelial electrical resistance (TEER) which is
often indicative of a restriction in paracellular flux.10 In addition, cells exhibited
increased localization of ZO-1, occluding, and claudin-5 to cell-cell junctions and a
flatter morphology.11 In order to test these conditions, the direct contact coculture system
was grown in serum for the first two days of culture to allow for proliferation and
confluence. After two days, serum-free media was added and compared to cell cultures
grown with serum for the extent of the study. To measure changes in paracellular
permeability, [C14]-mannitol and [C14]-sucrose were used.
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Figure 2.7.

Sucrose

Effect of Serum-Free Differentiation Conditions on [C14]-Mannitol

Permeability Across the Direct Contact Coculture Model. Data is means ± 1 standard
deviation of N=3 studies. *: p<0.05

Figure 2.7, indicates that in both cases, media containing serum for the extent of
the study provided a tighter monolayer. This may indicate that extended time without the
presence of serum caused hCMEC/D3 dedifferentiation and loss of some tight junction
structure or function. It should be noted that the cells used in the studies above utilized
primary porcine BMECs which may be less susceptible to dedifferentiation in serum-free
conditions than the immortalized hCMEC/D3s. Additional studies could be conducted to
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measure the effects removing serum later in culture and of reduced-serum conditions as
opposed to serum-free conditions.

Hydrocortisone
Hydrocortisone is an endogenous anti-inflammatory glucocorticoid hormone
which acts through inhibition of pro-inflammatory factors such as tumor-necrosis-factor
alpha (TNF-alpha). In vitro studies have shown that TNF-alpha signaling is responsible
for tight junction breakdown and increased paracellular permeability.12 While TNF-alpha
mRNA is not found in hCMEC/D3 lysates, it is possible that it may be produced by the
human astrocytes or found in the fetal bovine serum added to cell culture medium. To
counteract the possible effects of TNF-alpha from cell culture media, previous studies
were completed to examine the effects of adding 50 nM hydrocortisone to cell culture
media which resulted in substantial decreases in paracellular permeability and increases
in claudin-1, claudin-5, occludin, and VE-cadherin.12 Furthermore, previous unpublished
work in the Couraud lab suggests that an increased amount of hydrocortisone (1.4 μM)
provides additional monolayer tightening. However, due to the increased complexity
with the coculture, similar studies were conducted with 1.4 μM or 100 nM
hydrocortisone added at the start of hCMEC/D3 culture, or after two days of
proliferation.

These two days were given to allow the hCMEC/D3 cells to first

proliferate and differentiate.
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Figure 2.8. Effect of Hydrocortisone Concentration and Time of Addition on [C14]Mannitol Permeability. Here, 1.4 μM at the Start Represents Control Conditions. Data is
means ± 1 standard deviation of N=3 studies. *: p<0.05

Results in Figure 2.8 suggest that a larger hydrocortisone from the beginning of
cell culture represent the lowest [C-14]-Mannitol permeability. Interestingly, for lower
hydrocortisone levels, a substantial decrease in permeability was seen when
supplementing media after two days. Additional studies may be conducted to analyze
effects of later hydrocortisone addition to see if this trend continues.
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HEPES Concentration
While sodium bicarbonate is the most common buffer used in cell culture, a
number of organic buffers are also used.13 Sodium bicarbonate is often used due to its
low cost and ability to buffer around physiological pH in 37oC, 95% relative humidity,
and 5% CO2 conditions used in cell culture incubators. However, due to the chemical
nature of the sodium bicarbonate, if excess CO2 is not provided, it is released into the
atmosphere leading to high alkalinity up to pH 8.5. This could be problematic for
hCMEC/D3 cell culture as these cells are known to be susceptible to even relatively small
pH changes.14

In an attempt to counteract this, an organic buffer, HEPES, 4-(2-

hydroxyethyl)-1-piperazineethanesulfonic acid, was selected to buffer EBM-2 medium.
HEPES has a pH of approximately 7.4 at 37oC making it a good choice for
physiologically-relevant BMEC growth. Yet, HEPES is not without its own drawbacks.
In in vitro cultures of some cell lines, HEPES is known to reduce the uptake of amino
acids by glial cells.15 As the human astrocytes are a glial cell line, it is possible that
HEPES may be detrimental to the coculture model. In order to analyze possible toxicities
with the coculture, a broad range of HEPES concentrations from (10-50 mM) were tested
on both hCMEC/D3 monolayers and the direct contact coculture.
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Figure 2.9. Effect of HEPES Buffer Concentration on [C14]-Mannitol Permeability.
Data is means ± 1 standard deviation of N=3 studies. *: p<0.05. Note: All Coculture
Permeabilities are Significantly Lower (p<0.05) than hCMEC/D3 Permeabilities at the
same HEPES Concentration. Significance in the Figure is Represented as a Significant
Decrease over Control (10mM) HEPES Concentration for Coculture Data.

Interestingly, while the coculture was found to still be significantly less permeable
than hCMEC/D3 monolayers at all HEPES concentrations, higher HEPES concentrations
led to quantitatively lower [C14]-Mannitol permeability. However, it does appear that
some toxicities may be evident at 50 mM HEPES due to a non-significant increase over
25mM. As manufacturer-reported toxicities are usually found between 40 and 50 mM,
our findings correlate with literature. While HEPES appears to provide non-toxic
conditions at least up to 25 mM, further investigation is needed to determine the
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mechanistic pathway leading to the significant tightening found when increasing HEPES
buffer from 10 mM to 25 mM. This may be due to the increase in buffer capacity, or
small change in pH caused by increasing buffer concentration.16

However, some

literature suggests that HEPES may play a role in increasing ATP concentrations in
vitro.15 This increased ATP may possibly lead to a cascade of events leading to increased
tight junction protein expression or localization.

Lithium Chloride
Studies in animal primary endothelial cells suggest that activation of the Wnt/βcatenin pathway leads to increased expression of claudin and other tight junction proteins
by BMECs.17 While both expression and localization are necessary in tight junction
formation, an increased expression of claudins, especially claudin-5, which is thought to
be one of the main BBB phenotypic proteins, may lead to an increase in tight junction
formation and decreased paracellular flux.

A number of proprietary molecules are

available to upregulate the Wnt/β-catenin pathway, however, lithium chloride (LiCl), a
relatively cheap and obtainable compound is also known to stimulate this pathway
through inhibition of β-catenin phosphorylation and eventual degradation.18 In fact,
previous work on hCMEC/D3 monolayers has shown that 10 mM LiCl supplementation
led to 2-3 fold increases in claudin-3 and -5 expression and approximately 20% reduction
in Lucifer Yellow, a fluorescent paracellular marker, permeation.17 In order to test this
hypothesis, 10 mM LiCl was added to EBM-2 at the start of hCMEC/D3 culture or twodays after. These two days were given to allow the hCMEC/D3 cells to proliferate and
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become confluent as LiCl is also known to promote differentiation.

Premature

differentiation before reaching confluence may lead to incomplete monolayer formation
as little proliferation occurs after differentiation. Results of the study are shown below.
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Figure 2.10. Effect of 10mM Lithium Chloride on [C14]-Mannitol Permeability. Control
Conditions are Grown Without Lithium Chloride. Data is means ± 1 standard deviation
of N=3 studies. *: p<0.05

While literature suggests increased tight junction protein expression and reduced
paracellular flux in hCMEC/D3 monocultures, similar results were not seen in coculture
under the conditions tested. In fact, significantly increased paracellular permeability was
seen for cultures containing LiCl. However, as noted above, LiCl is known to promote
differentiation. It is possible that two days was not enough time for full hCMEC/D3
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confluence to be reached in coculture. This idea is upheld by a quantitative, though nonsignificant, decrease in permeability when adding LiCl on day 2 as well as Figure 2.3
which shows increased permeability of cocultures until day 5.

Calcium
Some investigation in our lab has led to the finding that the EBM-2 media,
manufactured by Lonza, contains a minimal amount of calcium (Stephen Carl Thesis,
2009). While the mechanism is not well understood, extracellular calcium concentration
is known to play a role in tight junction function. This was shown through addition of
EGTA and other calcium chelators which lead to the opening of tight junctions and large
increases in paracellular permeability.19 That being said, previous unpublished studies in
our lab have shown that adding excess calcium to EBM-2 media led to insignificant
changes in [C14]-Mannitol permeability across hCMEC/D3 monolayers. However, to
ensure low calcium levels aren’t responsible for high paracellular permeability in the
coculture model, 1mM calcium was added in excess and [C-14]-Mannitol and [C14]Sucrose permeability was measured.

Apparent Permeability [cm/s]

52

2.00E-05

Control

1.80E-05

1mM Calcium

1.60E-05
**

1.40E-05
1.20E-05
1.00E-05
8.00E-06
6.00E-06
4.00E-06
2.00E-06
0.00E+00
Mannitol

Sucrose

Figure 2.11. Apparent Permeability of [C14]-Mannitol and [C14]-Sucrose in Normal
EBM-2 (Control) and EBM-2 with 1 mM Excess Calcium Ion. Data is means ± 1
standard deviation of N=3 studies.**: p<0.01

Similar to previous hCMEC/D3 monoculture studies in our lab, Figure 2.11
shows insignificant changes in coculture [C14]-Mannitol permeability. In fact, for both
[C14]-Mannitol and [C14]-Sucrose excess calcium led to increased paracellular
permeability. Interestingly, significant changes were seen for [C14]-Sucrose, however, it
should be noted that this significance is in most part due to unusually small deviations.
While this study suggests that excess calcium may actually impair tight junction function
in our model, it should be noted that only a single excess calcium concentration was
measured and varying this excess concentration may result in differing results.
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Functional Drug Efflux
The optimization studies above, as well as previous media optimization by our lab
and other labs using the hCMEC/D3 cell line have mostly focused reduction in
paracellular permeability. While the exclusion of small hydrophilic molecules from
moving through paracellular tight junctions is one of the BBB’s main barriers to drug
delivery, efflux of hydrophobic molecules, preventing transcellular permeation, also
represents a significant barrier. Therefore, it is important to also measure changes in
functional hCMEC/D3 efflux when cocultured in direct contact with human astrocytes.
In order to assess functional efflux, two types of studies are common. The first is the
measurement of the directional permeability in both the apical-to-basolateral (AB) and
basolateral-to-apical (BA) directions. Due to the unidirectional efflux back into the
apical compartment, an efflux substrate should have increased permeation in the
basolateral-to-apical direction and reduced permeation in the apical-to-basolateral
direction. Therefore an AB/BA ratio greater than 2.5 or 3 is often believed to represent
the presence of drug efflux transporters. Additionally, efflux activity can be estimated
through uptake experiments. In this case, cells are seeded onto culture well plates instead
of Transwell® supports and the rate of cell uptake is measured over a defined time. In
this case decreases in the rate of uptake suggest increased efflux activity. These studies
are especially useful when trying to optimize conditions due to the low cost of well-plates
in comparison to Transwell® supports.
In order to examine efflux of the direct contact coculture model in comparison to
hCMEC/D3 monocultures the bidirectional permeability of 1μM [C14]-Verapamil was
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measured and can be seen in Figure 2.12. No change was seen in either direction when
comparing the mono- and cocultures. In addition, there were no significant differences in
AB or BA directional permeability in either model suggesting no functional efflux. This
is interesting as numerous previous reports, including those in our own lab, have shown
the functional presence of p-glycoprotein including bidirectional studies, uptake studies,
and localization by microscopy.4,6,20-22 However, upon further investigation, it was found
that Verapamil is both a P-gp substrate as well as an inhibitor (though we are
approximately 10-fold below reported Ki values) which may confound results.
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Figure 2.12. Apparent Permeability of [C14]-Verapamil in Apical-to-Basolateral and
Basolateral-to-Apical Directions for hCMEC/D3 and Coculture Models. Data is means ±
1 standard deviation of N=3 studies.
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As Verapamil was found to potentially be a conflicting substrate, further
investigation was done using [C14]-Paclitaxel. Additionally focus was moved to first
quantifying function efflux in the direct coculture system due to costs associated with the
studies.

Paclitaxel studies were run at 10 μM concentration in a similar fashion;

however, in this case bidirectional permeability was also measured in the presence of a pglycoprotein inhibitor, 5 μM Cyclosporine A (CsA).

Again, no significant differences

were seen between AB and BA permeability coefficients in Figure 2.13. CsA did lead to
a small increase in AB permeation, which may signify some inhibition, however, this is
complicated by a concurrent increase in BA permeability.
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Figure 2.13. Apparent Permeability of [C14]-Paclitaxel in Apical-to-Basolateral and
Basolateral-to-Apical Directions for Coculture Models with and without Cyclosporin A
Inhibition. Data is means ± 1 standard deviation of N=3 studies.
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This data seems to support, the conclusions found with Verapamil, however, to be
confident a final study was done measuring the bidirectional permeability of 5 μM
Rhodamine-123 (R123) with inhibition by 20 μM Verapamil. As noted above, while
Verapamil is a p-glycoprotein substrate, it also acts as an inhibitor at concentrations
above ~10 μM.23 Results in Figure 2.14 are slightly more encouraging as R123 showed
nearly significant (p=.058) increases in BA permeability over BA. In addition, these
differences disappeared in the presence of an inhibitor with a reduction in BA
permeability and an increase in AB. That being said, the BA/AB ratio is still well under

Apparent Permeability [cm/s]

2 which suggests that even if functional efflux is present it is at a low level.

1.40E-05

AB

1.20E-05
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1.00E-05
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4.00E-06
2.00E-06
0.00E+00
R123
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Figure 2.14. Apparent Permeability of Rhodamine-123 in Apical-to-Basolateral and
Basolateral-to-Apical Directions for Coculture Models with and without Verapamil
Inhibition. Data is means ± 1 standard deviation of N=3 studies.
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These studies all appear to contradict the results found by others who have shown
active efflux expression and function in the hCMEC/D3 model. At least in the case of
our lab’s hCMEC/D3 cells, functional expression of efflux proteins has been reduced or
lost completely. One speculation of why this may be is the high passage number used in
these studies. Studies were conducted around passage 45, and recent research suggests
that P-gp expression may be reduced after passage 40.22 However, even at the reduced
levels shown at higher passage numbers, the expression found was still relatively high.
In order to test this hypothesis, cells of lower passage number have been purchased and
will be tested in the future. Another possibility is a lack of polarized efflux expression in
our model. In this scenario, efflux would occur in both directions and any changes in AB
and BA permeability would be equivalent. One method to test this hypothesis would be
cellular uptake as even unpolarized expression will limit uptake into the cell. However, it
is possible that uptake by astrocytes in the coculture model could make delineation of
hCMEC/D3 uptake difficult. Finally, through discussion with others working with the
cell line, this problem does not seem to be solely ours. While not discussed in the
literature, it appears that this cell line has the tendency to gain and lose efflux expression
in culture which may limit its utility.
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CHAPTER 3. DEVELOPMENT OF A PHYSIOLOGICALLY
RELEVANT BLOOD-BRAIN BARRIER COCULTURE MODEL

Modified From: Kulczar C, Lubin KE, Ngendahimana A, Lefebvre S, Miller DW, Knipp
GT. Development of a Direct Contact Astrocyte-hCMEC/D3 Blood-Brain Barrier
Coculture Model. (In Submission)

3.1.

Introduction
The blood-brain barrier (BBB) is a highly restrictive barrier between the systemic

circulation and the brain parenchyma.1-5 The BBB functions to exclude harmful
xenobiotics while permitting the entry of nutrients and removal of waste allowing for a
neuronal environment optimal for development and function.6-8 One of the key elements
of the BBB is a continuous endothelium with the presence of exceedingly restrictive tight
junctions between brain microvessel endothelial cells. These tight junctions prevent the
paracellular movement of hydrophilic molecules and ions to a greater extent than
anywhere else in the body.9,10 This tightness is believed to be due, in part, to an increased
expression of claudin-3, 5, and 12 in brain microvessel endothelial cells compared to
microvessel endothelial cells in the periphery.11 In addition to tight junctions, BBB
endothelial cells also express a number of drug metabolizing enzymes, such as
cytochrome P450 enzymes (CYP450), and efflux transporters, such as P-glycoprotein (P-
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gp) and breast cancer resistance protein (BCRP), which act to efflux xenobiotics moving
transcellularly.12-14
Further investigation of the BBB reveals supporting cells, such as astrocytes and
pericytes, form a symbiotic, synergistic relationship with BMECs that significantly
enhances the barrier properties.3,15,16 Due to their close-knit interactions leading to BBB
formation, the collection of endothelial cells, astrocytes, and pericytes was coined the
neurovascular unit. Each of the cells play a role in creation of the barrier, and while tight
junctions between the endothelial cells are responsible for the barrier function itself, the
astrocytes and pericytes are thought to be necessary for co-differentiation with the
endothelial cells.17 Among other things, astrocytes are believed to be responsible for
regulating development of tight junctions, the movement of water and glucose across the
BBB, metabolism, and the localization of transporters.2 In addition, astrocytes highly
express CYP450 enzymes and may serve an important neuroprotective role by
metabolizing and removing many xenobiotics, including pharmaceutical compounds.18
Pericytes on the other hand, are thought to be important for production of soluble growth
factors as well as production and maintenance of an extracellular matrix rich in collagen,
fibronectin, proteoglycans, and laminin that is important for integrity of the BBB and
may be important for proper BBB differentiation.19-21
Due to the increasing importance of translatable knowledge of the BBB and
permeation across the barrier, a number of different in vitro models have been
established.8,17,22-32 Many of these models utilize primary human or animal BMECs.33
While primary human BMECs may provide the most ideal and relevant model, the
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availability of such tissues is minimal, reducing their utility for high throughput
screening.6 Due to the lack of human tissues, many attempts have been made to use
animal tissues as a surrogate. These cells are often of murine, bovine, or porcine origin.
Primary cells of animal origin have been shown to provide relatively high
transendothelial electrical resistance (TEER) indicative of the presence of developed tight
junctions.25,29,31,34 However, one must question the physiological relevance of these
models for drug screening, especially based on species differences including nonparacellular routes of permeation indicative of the vast majority of BBB permeable
compounds. Therefore, new models have been established making use of immortalized
human tissues which provide the relevance of a human cell line without the disadvantage
of short supply.
One of the most often used immortalized human BMEC cell lines is the human
cerebral microvessel endothelial (hCMEC/D3) cell line. The hCMEC/D3 cell line was
established through hTERT and SV40 large T antigen immortalization of endothelial
cells isolated from microvessels of a human temporal lobe.35 hCMEC/D3 cultures form
monolayers on collagen-coated surfaces and are contact inhibited lending themselves to
high throughput Transwell® permeation studies. Analysis of the cell line and has shown
similarities in morphology and protein expression between hCMEC/D3s and primary
human BMECs. However, hCMEC/D3s do not appear to form tight junctions consistent
with those found in vivo, reaching TEER values of only 30-50 Ω*cm2 compared to TEER
values of over 1000 Ω*cm2 in vivo in the frog.8,32,35-37 These leaky tight junctions may
allow paracellular movement of compounds that permeate by the transcellular route in
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vivo, leading to irrelevant permeability values. While optimization of culture conditions,
e.g. media, density, cell source, etc., has led to modest increases in monoculture TEER,
these values are still well below those seen in vivo.6,38
Due to the leakiness of these monocultures, many groups have examined methods for
reducing the paracellular permeability of these models. One approach is to use astrocyte
conditioned media.39 In these studies, soluble factors released by the astrocytes were able
to interact with BMECs to create a more in vivo-like environment that lead to enhanced
differentiation and reduced paracellular permeability. However, for hCMEC/D3 cultures,
non-significant changes were seen in TEER when using astrocyte conditioned media.27,35
Instead, the most significant reductions in paracellular permeability were seen when
astrocytes were grown on the basolateral side of the filter or on the plastic well surface in
the same Transwell® as the hCMEC/D3s (Figure 3.1A).8,32

While a reduction in

paracellular permeability of marker compounds and increases in TEER were seen for
both of these conditions, greater changes were observed in cells grown on the basolateral
side of the Transwell®.6 These models are likely more physiologically relevant due to the
symbiotic signaling and differentiation that is able to occur when both cell types are
grown in the same culture. In addition, the increased tightness seen when growing
astrocytes on the basolateral side of the Transwell® may reflect a closer proximity of
astrocytic-released factors to endothelial cells thus producing a greater response through
reduced dilution 28 Moreover, it is thought that the model in which cells are grown on the
bottom of the Transwell® permeable support may lead to tighter junctions due to the
ability of the astrocytic endfeet to migrate through the pores of the filter and interact with
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the BMECs through direct contact. However, it should be noted, that migration through
Transwell® supports, especially through 0.4μm pores which best support endothelial cell
culture, is infrequent.34,40
It is apparent from the studies mentioned above and analysis of the neurovascular
unit, that the interplay between BMECs and astrocytes may serve an important role in
differentiation of BMECs into providing a BBB phenotype. In addition, these studies
have shown the proximity of astrocytes and BMEC may be crucial.2,28,40 However, the
methods described in previous coculture models entails separating BMECs and astrocytes
by a filter support. While the Transwell® support is often depicted to be thin in cartoon
representations, the support is approximately 10μm thick and may represent a significant
barrier to cell-cell interactions. It is hypothesized that removing this obstruction and
allowing direct cell-cell contact may allow further symbiotic signaling and differentiation
to occur, which in turn may lead to further reduction in paracellular permeability and a
more in vivo relevant model. An illustration of the model is shown in Figure 3.1B. To
our knowledge, this is the first study that provides evidence that direct contact may
provide additional benefit to the coculture tightness and physiological relevance.
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A.

B.

Figure 3.1. Past (indirect) vs. current direct contact coculture models. A, previous direct
contact coculture model with BMEC and astrocytes separated by Transwell® permeable
filter support. B, current direct contact coculture model, with BMEC and astrocytes in
direct cell-cell contact. BMEC and astrocytes depicted in red and purple respectively.
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3.2

Materials and Methods

Materials
Trypsin, Phosphate Buffered Saline (PBS), Penicillin/Streptomycin, Type I Rat Tail
Collagen, Poly-L-Lysine, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
Buffer, Fibronectin, MaxgelTM, Hank’s Balanced Salt Solution (HBSS), Hydrocortisone,
human Basic Fibroblast Growth Factor (bFGF), Ascorbic Acid, and Fetal Bovine Serum
(FBS) were acquired from Sigma-Aldrich Company (St. Louis, MO). EBM-2 growth
media was manufactured by Lonza Group (Walkersville, MD). Lipid Concentrate was
obtained from BD Biosciences (Sparks, MD). 0.4 μm Transwell® 12 well plates and T75
flasks were made by Corning Lifesciences (Corning, NY). Radiolabeled compounds
were purchased from Moravek Biochemicals Inc. (Brea, CA). The hCMEC/D3 cell line
was graciously provided by Dr. Pierre Couraud of the Université Rene Descartes (Paris,
France), while human astrocytes, Human Astrocyte Media, and Astrocyte Growth Factor
were acquired from ScienCell Research Laboratories (Carlsbad, CA).
Methods
Cell Culture
The hCMEC/D3 cells were cultured in EBM-2 supplemented with FBS,
Penicillin/Streptomycin, bFGF, Hydrocortisone, Ascorbic Acid, Lipid Concentrate, and
HEPES buffer. Cells were maintained in a 5% environment at 37oC. HCMEC/D3 cells
were passaged when confluence reached approximately 80%, at which time trypsinized
cells were placed in a pre-collagenated (Type I) flask. Media was changed every other
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day. Human astrocytes were cultured under similar conditions in Human Astrocyte Media
supplemented with FBS, Astrocyte Growth Factor, and Penicillin/Streptomycin. Cells
were passaged approximately every 5 days into flasks pre-coated with Poly-L-Lysine.

Monoculture Studies
In hCMEC/D3 monocultures, cells were seeded at a density of 1 x105 cells/cm2 on
Corning Costar 12-well 0.4 μm polyester Transwells® pretreated with 65 μL of 1 mg/mL
Type I rat tail collagen and allowed to grow for 7 days.

For human astrocyte

monoculture, 4 x104 cells were seeded onto Transwells® coated with 2 μg/cm2 poly-Llysine and grown for 9 days prior to permeability studies.

Indirect Coculture Studies
Indirect coculture Transwells® were first pretreated with 65 μL of 1 mg/mL Type I rat
tail collagen in ethanol in the apical chamber and left to evaporate for 4 hours. Following
evaporation, the Transwells® were flipped and 2 μg/cm2 poly-L-lysine was added to the
basolateral side of the Transwells® and left overnight. Human astrocytes were plated on
the basolateral side of the flipped Transwells® at a density of 4 x104 cells/cm2 and left to
attach for 4 hours. Transwells® were then placed into the normal orientation and grown
for 48 hours. After this time, hCMEC/D3 cells were plated in the apical compartment at
a density of 1 x105 cells/cm2. The coculture was left to proliferate/differentiate in EBM-2
for an additional 7 days with media changes every other day before the permeability
studies were conducted.
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Direct Coculture Studies
For direct coculture studies, Transwell® inserts were coated with 2 μg/cm2 poly-Llysine and left overnight. Human astrocytes were then plated at a density of 4 x104
cells/cm2. Astrocytes were allowed to proliferate/differentiate for 48 hours in astrocyte
media. After 48 hours, media was removed and hCMEC/D3s were plated in EBM-2 at a
density of 1 x105 cells/cm2. The coculture was grown in EBM-2 with media changes
every other day for an additional 7 days before studies were conducted.

Permeability Studies
Permeability studies were performed at 37oC on a rocker plate in triplicate using
[C14]-labeled markers ([C14]-Urea, [C14]-Mannitol, [C14]-Sucrose, [C14]-Inulin,
[C14]-PEG-4000, and [C14]-Propranolol) at a concentration of 0.25 μCi/mL in HBSS. In
all studies, human astrocytes ranged from passages 6-12 while hCMEC/D3 cells ranged
from passage 36-48. Before all permeability studies, cells were washed twice with PBS
before equilibrating in HBSS for 20 minutes shortly before the study. 100μL samples
were taken at 15, 30, 45, 60, and 90 minute time points. 4mL of scintillation cocktail was
added for analysis by scintillation counting. Permeability coefficients (cm/s) were
obtained through the following equation:

𝑃𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡

𝑑𝑀
𝑑𝑡
=
𝐶0 ∗ 𝑆𝐴 ∗ 60
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where

𝑑𝑀
𝑑𝑡

is the rate of radionucleotide transfer across the cell layer, 𝐶0 is the initial donor

concentration, 𝑆𝐴 is the surface area of the Transwell® filter support, and 60 represents a

correction factor from minutes to seconds.

Statistics
Permeability studies were compared using a two-tailed unpaired student’s t-test with
n=3. Studies with p-values less than 0.05 were considered to have significant differences.

3.3 Results
In order to delineate changes in BBB phenotype upon coculture with human
astrocytes, permeability was measured with a number of marker compounds. However,
the model was first optimized for minimal paracellular permeability. Extensive
optimization of hCMEC/D3 and astrocyte seeding density, basement matrix, media, and
seeding time were performed prior to the following studies (data not shown). The current
method proved to be superior to other growth conditions investigated.

Direct Contact Coculture
As noted above, the hCMEC/D3 cell line, while tighter than other immortalized
human BMEC cells, possess tight junctions that lack ideal physiological relevance. To
investigate changes in tight junction pore radius, five marker compounds of varying
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hydrodynamic radii were used to determine changes in paracellular permeability. As
expected, increases in hydrodynamic radii lead to decreased apparent permeability
coefficients for paracellular markers. However, the extent of changes in permeability
varied between mono- and coculture, likely due to the effects predicted by the Renkin
molecular sieving function as the pore radii approaches the size of the sieved
molecule.31,36,41,42 Although, it should be noted that in the presence of astrocytes the
assumptions made by the Renkin function including the presence of a single pore, varied
and increased tortuosity and porosity exists, thus the effects of permeation across the
astrocytes cannot be easily corrected to obtain a pore radius.
As shown in Figure 3.2, significant changes between the mono- and coculture were
seen for [14C]-urea (2.96 ± 0.11 x10-5 cm/s and 2.43 ± 0.15 x10-5 cm/s; p=0.030), [14C]mannitol (1.98 ± 0.05 x10-5 cm/s and 1.52 ± 0.07 x10-5 cm/s; p=0.0004), [14C]-sucrose
(1.52 ± 0.13 x10-5 cm/s and 1.17 ± 0.008 x10-5 cm/s; p=0.005), and [14C]-inulin (8.46 ±
0.02 x10-6 cm/s and 7.55 ± 0.3 x10-6 cm/s; p=0.034) respectively. Insignificant (p>0.05)
changes were seen for [14C]-PEG-4000 (3.93 ± 0.36 x10-6 and 3.57 ± 0.10 x10-6 cm/s;
p=0.227) respectively.
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Figure 3.2. Apparent permeability for 5 paracellular [14C]-labeled markers of various
hydrodynamic radii. Studies were run in triplicate and subjected to student’s T-Test.
Significant changes are noted with an asterisk (*) for p<0.05 and (**) for p<0.01. Error
bars represent 1 standard deviation (n=3).

Indirect Contact Coculture
It is well established that changes in culture conditions and cell source can cause
significant changes in protein expression of drug metabolizing enzymes, efflux proteins,
etc,, which are the focus of ongoing studies.43,44 In addition, modifications in media have
been shown to have considerable effects on BMEC differentiation and tight junction
formation.32,45,46 To establish an internal lab control, an indirect coculture model was also
run to investigate differences in paracellular permeability when culturing human
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astrocytes in direct contact with hCMEC/D3 cells. Figure 3.3 shows that direct contact
leads to significant reduction in permeation compared to indirect contact of both [14C]mannitol (1.52 ± 0.07 x10-5 cm/s and 1.89 ± 0.15 x10-5 cm/s; p=0.038), and [14C]-sucrose
(1.17 ± 0.008 x10-5 cm/s and 1.53 ± 0.12 x10-5 cm/s; p=0.035) respectively.

2.5

*

Apparent Permeability [10-5 cm/s]
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0
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Direct Contact
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Indirect Contact

Figure 3.3. Apparent permeability of [14C]-Mannitol and [14C]-Sucrose across direct and
indirect contact cocultures. Studies were run in triplicate and subjected to student’s TTest. Significant changes are noted with an asterisk (*) for p<0.05 and (**) for p<0.01.
Error bars represent 1 standard deviation (n=3).
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Passive Transcellular Permeability
To investigate the effects on transcellular permeation when culturing human
astrocytes and hCMEC/D3 cells in direct contact, [14C]-propranolol apparent
permeability was measured. Due to its high lipophilicity, the majority of propranolol is
uncharged at physiological and a presumed minimal paracellular permeation it was
selected as a marker for transcellular permeation. Figure 3.4 shows that insignificant
changes in [14C]-Propranolol apparent permeability were seen between hCMEC/D3 and
direct contact coculture (1.91 ± 0.19 x10-5 cm/s and 1.61 ± 0.04 x10-5 cm/s; p=0.103).
This may indicate transcellular permeation through hCMEC/D3 cells followed by passive
transport across the human astrocyte layer which don’t possess tight junctions. However,
these values are nearly 3-fold lower than astrocytes grown in monoculture (4.58 ± 0.41
x10-5 cm/s). This makes it difficult to assess the effect of astrocytes on transcellular
permeation of [14C]-propranolol across the hCMEC/D3 monolayer.
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Figure 3.4. Apparent permeability of [14C]-Propranolol, a passive transcellular
permeability marker. Non-significant changes (p<0.05) were seen between monoculture
and coculture. Error bars represent 1 standard deviation (n=3).

3.4

Discussion
Previous research has demonstrated that the hCMEC/D3 cell line forms a barrier that

is a functionally and physiologically relevant model for human BMECs.

This is

predicated on the fact that hCMEC/D3 cells possess a similar morphology and protein
expression as found in primary human BMECs.35,47

In addition, the cell line is
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immortalized, of human origin, can be grown in monolayers, and is contact inhibited,
properties which all lend themselves for use in in vitro permeability screening.32
However, hCMEC/D3 monolayers lack the tightness found in vivo which may lead to
increased paracellular permeation of drug molecules that in turn may obfuscate the ability
to predict transcellular permeation that is observed when studying in vivo brain
distribution.6 As has been previously shown, coculturing hCMEC/D3 cells with
astrocytes has led to pronounced decreases in paracellular permeability for BMECs
which may mitigate this problem.48 Moreover, the presence of the astrocytes enables a
more relevant understanding of the transport across the in vivo neurovascular unit.

Since the discovery of the neurovascular unit, this interplay between BMECs and
astrocytes at the BBB has been studied. While there are still unknowns, a lot of their
interactions have been elucidated.2,13,49,50 For BMECs, it has been shown that astrocytes
play an important role in tight junction development, localization and expression of
transporters, as well as upregulation of metabolic enzymes, which are currently being
investigated.32,35,50 In addition, some of these interactions may require symbiotic crosstalk
leading to co-differentiation17,51, and while some of these adaptations can be seen with an
indirect coculture of BMECs with astrocytes in vitro; leakiness of the tight junctions is
still significantly higher than in vivo conditions.6 It is hypothesized that one reason for
continued leakiness is an inability for astrocytes to form true direct contact with the
BMECs in this model due to the presence of the Transwell® permeable support. This
lack of contact may hinder cross-talk between endothelial cells and astrocytes. For this
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reason, a direct contact model with hCMEC/D3 cells seeded directly onto human
astrocytes was investigated.

Due to the importance of limiting paracellular permeation in in vitro BBB cell
models, changes in permeation of five paracellular markers of various size; [14C]-urea,
[14C]-mannitol, [14C]-sucrose, [14C]-PEG-4000, and [14C]-inulin were measured (Table
3.1). When comparing permeation through hCMEC/D3 monolayers to the coculture, all
markers trended toward a reduction in paracellular permeation for the coculture. For the
largest marker, PEG-4000, results were insignificant (p>0.05), however, this isn’t
unexpected as permeation through the hCMEC/D3 monolayer was sufficiently slow it is
unlikely further pore size reduction would lead to sizable changes in permeability. A
similar story can be said of the smallest marker, urea. While significant reduction was
seen (p<0.05), it is apparent that this model is still unable to prevent permeation of polar
molecules in this very low molecular weight range. The most significant changes were
seen for mannitol and sucrose (p<0.01).
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Table 3.1. Comparison of molecular weight and molecular radii with apparent
permeability of paracellular model compounds.

Marker

Molecular
Weight

Stokes Radius
(Å)

Hydrodynamic Radius
(Å)

Papp
(x10-5 cm/s)

Urea
Mannitol
Sucrose
Inulin
PEG-4000

60
182
342
5000
4000

1.7
3.6
4.6
13.9
16.4

1.8
4.3
5.2
10
15.9

2.43 ± 0.155
1.52 ± 0.069
1.17 ± 0.008
0.754 ± 0.030
0.357 ± 0.010

To investigate the impact of direct coculture, an indirect coculture with astrocytes on
the basolateral side of the Transwell was also examined. As mentioned, it is often
difficult to compare models between different labs due to differences in culture protocol,
media selection, passaging, and cell source.43,44

Therefore, the indirect model was

established under the same conditions and protocols as the direct contact coculture. As
was hypothesized, a significant decrease in [C14]-Sucrose apparent permeability was
seen when the astrocytes were in direct cell contact. Further investigation is needed to
determine the underlying factors leading to this increased tightness.

To assess passive transcellular permeation the apparent permeability of [14C]propranolol was measured. Propranolol is often used as a passive transcellular marker
due to its high octanol:water coefficient leading to almost exclusive transcellular
permeation.52

Due to the extra cell layer in the coculture model, it was expected that

transcellular permeation would be reduced.

While permeability was reduced in the
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coculture, changes between mono- and coculture weren’t significant (p>0.05). To further
examine this discrepancy, [14C]-propranolol permeability was also measured across
human astrocyte monolayers and was found to be approximately three-fold higher than
hCMEC/D3 monolayers or the direct contact coculture.

This finding validates the

coculture permeability data as the hCMEC/D3 cell layer appears to be the rate-limiting
barrier to permeation. While astrocytes do play a role in our model, it is unknown if there
is a significant contribution of paracellular flux for propranolol that may obfuscate
transcellular permeation.

While propranolol is unlikely to cross the tight junctions

between endothelial cells, astrocyte end feet are known to be much further apart with
pores 20-30 Å wide which may allow greater paracellular movement.

Therefore,

additional studies are required to understand differences between the apparent
permeabilities for hCMEC/D3 and human astrocyte monocultures particularly to
elucidate the mechanism of transport across the human astrocyte layer.

Overall, this proof-of-concept study suggests direct contact coculture of human
astrocytes and hCMEC/D3s leads to some tightening of the leaky tight junctions often
found in hCMEC/D3 monoculture with minimal modification to other routes of
permeation. While this model is still significantly leakier than in vivo conditions it
represents an improvement in the paracellular leakage observed in many cell culture
models and an advancement in physiologically relevant screening models for determining
passive diffusion properties of drugs in the BBB. It should also be noted that while in
vivo tightness would be ideal, it may be unnecessary for drug screening. While current
TEER values are much lower than found in vivo, it is possible that small changes in tight
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junction pore radii will lead to very large increases in TEER.41 Due to the nature of
paracellular permeation, these large changes in TEER may have little effect on
paracellular permeation due to the difference in the hydrodynamic size of ions being
measured (sodium, potassium, calcium, chloride, magnesium, etc vs. drug molecules).31,53
That is, NCEs targeted to the brain are often much larger and more lipophillic molecules
than the ions whose movement across the cellular barrier determine TEER. In addition,
the vast majority of all NCEs aren’t as small or polar as urea, mannitol, or even sucrose.
TEER is also dramatically influenced by several other factors like ionic strength, buffers,
and temperature that can be confounding variables.

Lastly, species differences are a major cofounder in translation of preclinical
screening to humans.

Differences in morphology, function, and regulation are all

common. Since the common goal is to expedite human translation, it may be better in
theory to use a leaky human model than a tight animal model for the screening of
pharmaceutical molecules, provided the human model can discriminate between
compounds in series. This will reduce some issues such transport and enzyme affinities
and capacities observed between species and better enable an assessment of transcellular
permeation in vivo in humans.

3.5

Conclusion
As the occurrence of neurological diseases rise along with the number of druggable

targets and compounds, a more relevant and robust in vitro cell culture method has
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become of paramount importance for preclinical screening and lead candidate selection
and optimization. The hCMEC/D3 cells have been shown to be functionally similar to
primary brain endothelial cells, however, their main downfall has been the presence of
leaky tight junctions. These leaky tight junctions obfuscate the delineation of transcellular
routes of permeation of many compounds and potentially lead to inaccurate in vivo
predictions. Therefore, it is believed that reducing paracellular permeation to levels
closer to that found in vivo may lead to a more robust BBB model.
Some promise has been shown in the reduction of paracellular permeability through
coculture with astrocytes.

However, current models often utilize indirect contact

methods in which endothelial cells and astrocytes are separated by the Transwell®
permeable support. Here it is shown that direct contact coculture of human astrocytes and
hCMEC/D3 cells leads a significant decrease in permeation of paracellular markers. This
methodology may serve as a better model for further optimization and in vivo prediction.
In addition, seeding of both cell types onto the apical chamber of the Transwell® is likely
to be much more conducive to high-throughput screening. Though, further investigation
including microscopy, transcriptomic and proteomic analysis, and drug screening must be
completed to confirm in vivo relevancy, it is believed that this model is a step in the right
direction for enhancing the ability to screen neurotherapeutic and neurotoxic agents.
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CHAPTER 4. CYS34-PEGYLATED HUMAN SERUM ALBUMIN
FOR DRUG BINDING AND DELIVERY

Adapted With Permission from From: Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A.
2015. Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery.
Bioconjug Chem 26(5):941-949. Copyright 2015 American Chemical Society

4.1

Introduction

Protein function and recognition can be rationally modified by the covalent
ligation of molecular structures such as optical tags1, targeting ligands2, carbohydrates3,
and polymers.4,5 However, coupling methods that rely on available amines or carboxylic
acids for amide bond formation typically have poor regioselectivity, and can result in
intra- or intermolecular crosslinks that lead to protein denaturation, aggregation, or
general loss of function.6 Site-specific ligation methods are highly desirable for
introducing additional functionality to proteins without disrupting other physicochemical
properties. A useful alternative to amide bond formation involves the chemoselective
addition of alkylmaleimides to exposed cysteines.7 This method of conjugation has little
to no effect on the electrostatic surface potential of proteins at physiological pH, and is
thus less likely to induce unintended changes in secondary or tertiary structure. N- and
C-modified proteins have the intrinsic drawback of having different net charges relative
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to the native protein, which can affect their conformational behavior, dispersion stability,
aggregation kinetics, biomolecular recognition, and catalytic activity.6,8,9
PEGylation (i.e. the ligation of one or more polyethylene glycol chains to external
residues) is a widely used tactic to modify the pharmacokinetic properties of drug
carriers10,11 and protein-based biologics.12,13 Covalently attached PEG chains can stabilize
proteins by providing a surrogate hydration shell,14 or prevent denaturation by limiting
conformational freedom.15 While much attention has been paid to antibodies and other
"functional" biomolecules, passive proteins such as human serum albumin (HSA) are also
important candidates because of their putative roles in drug solubilization and delivery.
HSA's native role as a plasma carrier makes it an ideal candidate for transporting
hydrophobic drugs that possess higher binding affinities from the bloodstream into
extravascular tissue space.16,17 HSA is thought to facilitate drug permeation by passing
through endothelial layers via caveolar-mediated transcytosis.18,19 As one of most
abundant proteins in the plasma (35−50 mg/mL) ,20 HSA forms aggregates reversibly and
can accumulate passively in tumor tissue due to the enhanced permeability and retention
(EPR) effect.21,22 In this regard, we note that HSA-based formulations have been
characterized as nanoparticles ex vivo, but are thought to disperse into monomeric form
soon after entering the bloodstream.23 This suggests that the pharmacokinetic properties
of HSA may be tailored by judicious structural changes.
Interest in albumin-based drug delivery has been increasing due to the favorable
pharmacology of HSA, its low immunogenicity, and its current availability in
recombinant form. A well-known example of albumin-based formulation is HSA-bound
paclitaxel (Abraxane®), currently being used for the treatment of several late-stage

93
cancers.24,25,26 Paclitaxel (PTX) is a powerful antimitotic that induces apoptosis in rapidly
dividing cells;27 however, its therapeutic efficacy has been compromised by poor water
solubility or by surfactants with peripheral side effects (e.g., Cremophore EL).28,29,30 The
clinical success of Abraxane® confirms the benefits of HSA as a carrier of poorly soluble
drugs like PTX; nevertheless, adverse side effects such as moderate neuropathy and
neutropenia persist,26,31,32 indicating the need to further optimize drug loading and
delivery.
PEGylated HSA has been prepared by conventional amide ligation, and shown to
provide significant enhancements in its pharmacokinetic profile for drug delivery.33
However, most studies have been conducted by modifying the acidic or basic residues on
albumin, and the poor regioselectivity of amide-based ligations render these formulations
vulnerable to unintended changes in structure or colligative properties. For example, NPEGylation reduces the volume of the hydrophobic binding cavity in the second R-helix
domain, despite overall retention of HSA size and shape.34
Both HSA and its congener bovine serum albumin (BSA) possess a free thiol
residue at Cys-34, which presents the option of site-specific S-PEGylation using
maleimide chemistry.35,36 S-PEGylation of albumins can be performed with minimal
perturbation to pre-existing disulfide bridges with subsequent retention of protein
structure, as demonstrated in the case of PEG-(C34)BSA,35 and can increase its
circulation lifetime relative to unmodified albumins, as demonstrated in a rat model with
PEG(C34)HSA.36 These reports indicate that S-PEGylation at Cys-34 is an appealing
alternative to amide-based ligations for developing albumin-based carriers with tailored
pharmacological properties. It is worth mentioning that maleimide-based reagents have
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also been developed for PEGylation across disulfide bonds,37,38 but are not immediately
relevant for proteins bearing free thiols.
In this article we characterize the carrier properties of two mono-PEGylated HSA
derivatives with site-specific conjugation at Cys-34, prepared on a multigram scale using
maleimide-terminated mPEG chains having molecular weights of 5 and 20 kDa. SPEGylation produces minimal perturbations in conformation or solubilization of PTX,
but significantly increases HSA's propensity to self-assemble into protein nanoparticles
as characterized by nanoparticle tracking analysis (NTA). We also investigate the
permeation of PTX through monolayers of human umbilical vascular endothelial cells
(HUVEC) and brain microvascular endothelial cells (hCMEC/D3) with and without
PEG(C34)HSA conjugates, and evaluate the therapeutic efficacy of PTX-loaded
PEG(C34)HSA against MCF-7 breast cancer cells relative to native HSA (n-HSA). We
find that C34-PEGylation has essentially no negative impact on PTX loading and
subsequent permeation across cell monolayers. On the other hand, PEG(C34)HSA
conjugates provide substantial increases in the transport and cytotoxicity of PTX
delivered to MCF-7 cells, with negligible toxicity from PEGylated HSA alone.

4.2

Materials and Methods

Materials
Recombinant HSA was obtained from GenLantis (San Diego, CA); mPEGmaleimide was obtained from Laysan Bio (Arab, AL); hydrocortisone, Hank’s balanced
salt solution (HBSS), polystyrene T-75 flasks, and Transwell permeable supports were
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purchased from Sigma-Aldrich (St. Louis, MO). Paclitaxel was obtained from LC
Laboratories (Woburn, MA); radiolabeled [14C]paclitaxel ([14C]PTX) was purchased
from Moravek Biochemicals (Brea, CA). DMEM media, penicillin/streptomycin, and Lglutamine were obtained from Corning Cellgro (Manassas, VA); fetal bovine serum was
obtained from Atlanta Biologicals (Atlanta, GA); MTT reagent was obtained from RPI
(Mount Prospect, IL); EGM-2, EBM-2, and basic fibroblast growth factor were obtained
from Lonza (Walkersville, MD). MCF-7 cells were obtained from the Purdue Center for
Combinatorial Chemical Biology; HUVEC cells were obtained from the American Type
Culture Collection (ATCC; Manassas, VA); hCMEC/D3 cells were provided by Dr.
Pierre-Olivier Couraud at Institut Cochin (Paris, France). Phosphate buffer solution
(PBS) was prepared by tenfold dilution from a concentrated stock containing 80 g NaCl,
2 g KCl, 4 g Na2HPO4, and 2 g KH2PO4. All solutions were prepared using initially
deionized water using a Milli-Q ultrafiltration system from Millipore (Bedford, MA) with
a measured resistivity above 18 MΩ∙cm, passed through a 0.22-μm filter to remove
particulate matter.

Gram and Multigram Synthesis of PEG(C34)HSA conjugates
In a typical reaction, powdered HSA (1.0 g, 15.1 µmol) was dissolved in 40 mL
of sterilized PBS (adjusted to pH 6.5) in a 100-mL glass round-bottomed flask. The PBS
was passed through a 0.2-μm syringe filter prior to use, and the mixture was stirred for 15
minutes. mPEG5K -Mal (155 mg, 31 µmol) or mPEG20K-Mal (620 mg, 31 µmol) was
dissolved in 10 mL of sterilized PBS (pH 6.5) and added in 1-mL portions over 1 minute
to the stirred HSA solution. The mixture was placed in a 37 °C bath and stirred for 20
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hours, then cooled to room temperature. Solutions of S-PEGylated HSA were transferred
to dialysis membrane tubings (MWCO 12.4 kDa for PEG5K-HSA; MWCO 50 kDa for
PEG20K-HSA) and gently agitated in 500 mL of deionized water to remove salts and
excess mPEG-Mal (2 rounds, > 1 h each). Approximately 90% of each PEG(C34)HSA
was set aside for cell culture studies; the remainder was subjected to additional dialysis
for characterization. PEG(C34)HSA conjugates could be lyophilized and stored in the
dark at 4 °C.
For PEG(C34)HSA conjugates prepared on a multigram scale, purifications were
performed with an Amicon stirred ultrafiltration cell (180 mL) equipped with a cellulose
membrane filter (100 kDa MWCO), both from Millipore. Reaction mixtures were
concentrated to gelatinous slurries (ca. 10 mL) then redispersed in deionized water to
maximum volume, and repeated for up to 6 cycles. The rate of filtration ranged from over
10 mL/min to under 1 mL/min, depending on the concentration of residual mPEG-Mal in
the retentate.

Protein Characterization
Matrix-assisted laser desorption ionization mass spectra (MALDI-MS) were
obtained using an Applied Biosystems Voyager DE PRO spectrometer, equipped with a
nitrogen laser (337 nm) and a time-of-flight mass analyzer.

Positive-ion MS were

obtained in the linear mode using an accelerating voltage of 25 kV, grid voltage of 94%,
and extraction delay time of 98 nsec. The m/z range for this study was 10
−100 kDa,
using 150 laser shots per spectrum and sinapinic acid as the matrix material.
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Circular dichroism (CD) spectra were obtained using a Jasco J-810
spectrophotometer. Protein samples were prepared in halide-free phosphate buffer and
diluted to 1 µM. The instrument was flushed with nitrogen for 1 hour prior to use; spectra
were collected in triplicate from 190−260 nm at a scan rate of 7 minutes at 25 °C, with
data averaging performed after background subtraction. Attenuated total reflectance
infrared (ATR-IR) spectra were acquired using a Nicolet Nexus 670 FT-IR, under
constant nitrogen flow. Samples were prepared by depositing 1 mL of solution onto the
ATR crystal, then dried under a nitrogen stream until a thin film was obtained. The
sample chamber was purged for 20 minutes prior to collecting data.
High-performance liquid chromatography (HPLC) analyses were performed on
100-μL aliquots of PEG(C34)HSA after extensive dialysis, using an Agilent 1100 Series
HPLC with a Zorbax XDB-C8 column (Agilent, 4.6 mm × 15 cm). Gradient elutions
were performed using 33−66% aqueous CH 3CN with 0.1% trifluoroacetic acid (TFA) at a
flow rate of 0.75 mL/min; the column was equilibrated at 33% CH3CN for at least 30
minutes prior to sample injection. Proteins were detected by absorbance at 280 nm, with
yields determined by peak area integration. Levels of free mPEG-Mal were determined
by HPLC at 215 nm, using a Zorbax XDB-C8 column with a gradient elution of 35−45%
CH3CN plus 0.1% TFA (5-kDa mPEG-Mal), or a Phenomenex C18 reversed-phase
column (2.0 mm × 5 cm) with a gradient elution of 30−90% CH 3CN plus 0.1% TFA (20kDa mPEG-Mal), with calibrations against a reference sample. In both cases, the amount
of residual Mal-mPEG after six rounds of ultrafiltration was less than 1 wt%.
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Particle Characterization
Nanoparticle tracking analysis (NTA) was performed using a Nanosight LM-10
system equipped with a blue laser (λ= 405 nm), with data analysis supported by NTA
v.2.3.5.0033 (Build 16).39 NTA was performed using PBS (pH 6.5) stored in
polyethylene containers. The imaging chamber was cleaned with acetone and a
microfiber cloth prior to use, then washed with particle-free water until no background
signals were observed. Water was removed from the NTA chamber with a sterile plastic
syringe just prior to use, and replaced with protein solution−0.1
(1.0 mg/mL). Three
tracking videos were collected per sample; 50 μL of fresh solution was injected in
between each run to prevent protein aggregates from settling, followed by a 60-second
recording at a shutter speed of 700 and a gain of 400. The number of tracks per run varied
from 300 to 2000, depending on concentration. Hydrodynamic size analysis was derived
from number and volume particle distributions, with population samples based on the
number of tracks accumulated over several runs. Optimized parameters for video analysis
(advanced mode) include a detection threshold of 10, 9 × 9 blur setting, and automated
settings for track length and minimum particle size.

HSA−PTX Formulation
PTX-HSA formulations were produced from freshly prepared stock solutions of
PTX in DMSO (585 μM) and PEG(C34)HSA or n-HSA in PBS adjusted to pH 6.5 (150
μM). PTX solutions were diluted serially with PBS to concentrations at ×40above the
target dose. PTX and HSA stock solutions were then combined in a 1:1 v/v ratio (0.4 mL
total) and allowed to stand for 4 hours at room temperature, prior to use. 10-μL aliquots
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of HSA−PTX solution were added to 190 μL of cell culture media in 96 -well plates
containing MCF-7 cells at 10−20% confluence. DMSO concen trations were 0.1% v/v or
less.

Cell Permeation Studies
HUVEC and hCMEC/D3 cells were cultured in T-75 flasks at 37 °C, 5% CO2,
and 90% humidity. HUVECs were cultured in EBM-2 supplemented with Lonza EGM-2
SingleQuots®. hCMEC/D3 cells were cultured in EBM-2 supplemented with 5% FBS,
1× penicillin
−streptomycin, 1 ng /mL basic fibroblast growth factor, 1.4 μM
hydrocortisone, 5 μg/mL ascorbic acid, 1% chemically defined lipid concentrate, and 10
mM HEPES buffer. After thawing, cells were passaged at least three times before
transport studies with media changes every other day.
Transport studies were performed in the apical to basolateral direction in triplicate
wells simultaneously. HUVECs were seeded between passages 6−10, while hCMEC/D3
cells were seeded at passages 34
−42. Cells were seeded onto collagen -coated, 0.4-μm
polyester Transwells®, at a density of 50,000 cells/cm2 for HUVECs and 70,000 cells/cm2
for hCMEC/D3 cells. HUVEC and hCMEC/D3 cells were allowed to proliferate and
differentiate for 7 and 14 days respectively, with exchange of cell culture media every
other day. Confluent cell monolayers were washed twice with PBS then equilibrated for
30 minutes in HBSS, just prior to permeability studies. Formulations containing [14C]PTX were added to the apical side of the Transwell® plate, which was kept on a rocker
tray as aliquots were removed from the donor compartment at 15, 30, 45, 60, and 90
minute time points. Initial and remaining donor as well as cell lysate samples were also
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taken for permeability and mass balance calculations. 100 μL samples were diluted in 4
mL EcoLite® scintillation fluid and counted for 5 minutes on a Beckman Coulter LS 6500
scintillation counter. Apparent permeability (Papp) coefficients were determined using the
following equation:
𝑃𝑎𝑝𝑝 =

𝑑𝑀
1
∙
𝑑𝑡 𝑆𝐴 × 𝐶0 × 60

where dM/dt (counts/min) is the steady-state rate of mass transfer, SA (cm2) is the surface
area of the apical membrane, and C0 (counts) is the initial donor concentration. Studies
were compared using an unpaired, two-tailed Student’s t-test.

Cell Viability Assays
Mitochondrial oxidation assays using the tetrazolium dye MTT were performed as
previously described40 but using MCF-7 breast cancer cells, which were cultured in T-75
flasks and complete DMEM media with 10% fetal bovine serum (FBS), 1% L-glutamine,
and 1% penicillin/ streptomycin prior to plating. In a typical experiment, 96-well
microtiter plates (5,000 cells/well) were incubated overnight in 200 μL of media to
approximately 10% confluence. Solutions in each well were replaced the following day
with 190 μL of fresh media and 10 μL of PTX-HSA formulation, followed by 5 days of
incubation at 37 °C under a 5% CO2 atmosphere. The media was removed and replaced
with 190 μL fresh media and 10 μL 0.5% MTT, incubated at room temperature for 14
hours, then replaced with 200 μL DMSO for homogenization. Absorbance measurements
were recorded on a VersaMax microplate reader at 570 nm with background subtraction;
cell viabilities were normalized to a negative control group (having reached
−90%
70
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confluence over 5 days). Experiments were run in triplicate with errors representing one
standard deviation; two-tailed probability values were obtained by Student’s t-test.

4.3

Results and Discussion

Synthesis and Characterization of PEGylated HSA Adducts
Following an earlier reported procedure,36 PEG(C34)HSA adducts were prepared
at 37 °C in mildly acidic PBS (pH 6.5) by combining n-HSA (25 mg/mL) with 2 or 4
equivalents of 5-kDa or 20-kDa mPEG-Mal (Scheme 1). Maintaining a pH slightly below
7 helps to keep HSA in conformations that shield its internal disulfide bonds from other
solutes.41 Analytical samples of S-PEGylated HSA were obtained by HPLC purification,
whereas protein mixtures synthesized on a multigram scale were separated from
unreacted mPEG-Mal by stirred ultrafiltration. Recombinant HSA was used instead of
plasma-derived HSA, which reduces the risk of infection from unknown viruses or prions
that may be present in the latter. Recombinant and plasma-derived HSA have been
shown to be identical in structure.42
MALDI-MS and analytical HPLC were used to assess the degree of PEGylation:
n-HSA produced a strong peak at m/z 66,553,43 whereas PEG5K- and PEG20K(C34)HSA
produced additional peaksets centered at 71,984 (+5,431 amu) and 87,694 (+21,141
amu), respectively (Figure 4.1a‒c). HPLC analysis on dialyzed samples indicated that
treatment of n-HSA (Rt 6.4 min) with two equivalents of 5-kDa mPEG-Mal supported a
72% conversion into PEG5K(C34)HSA (Figure 4.1e), whereas treatment with two
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equivalents of 20-kDa mPEG-Mal supported a 48% conversion into PEG20K(C34)HSA
(Figure 4.1f). The conversion efficiency was not affected by changes in reaction time,
temperature or pH, but increasing the amount of 20-kDa mPEG-Mal to four equivalents
increased the conversion of PEG20K(C34)HSA to 77%. It should be noted that the HSA
was not pretreated with reducing agents, which can further optimize maleimide addition
to free cysteines;44 therefore, the yields reported here should be viewed as a lower limit.
We also note that ultrafiltration of PEG(C34)HSA from excess mPEG-Mal on a
multigram scale was initially tedious due to the high viscosity of the retentate but became
more efficient after several washings, with less than 1 wt% mPEG after six cycles
according to HPLC. All subsequent studies using PEG(C34)HSA were performed with
protein mixtures prepared from a 2:1 ratio of mPEG-Mal to n-HSA, and purified by six
cycles of ultrafiltration.
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Scheme 4.1. Synthesis of PEG(C34)HSA using 5- or 20-kDa mPEG-maleimide (Mal);
PEG chain truncated for clarity.

a

b

c

d

e

f

Figure 4.1. (a‒c) MALDI-MS analysis of n-HSA (m/z ~66.5 kDa), PEG5K(C34)HSA (m/z
~72.0 kDa), and PEG20K(C34)HSA (m/z ~87.7 kDa); (d‒f) HPLC traces of n-HSA (as
received), HSA treated with 2 equiv mPEG5K-Mal or 2 equiv mPEG20K-Mal.
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ATR-IR analysis confirmed retention of the PEG chain after exhaustive dialysis,
with a strong peak at 1090 cm-1 corresponding to C−O stretching modes, and minimal
differences in the amide peak region relative to n-HAS. Circular dichroism analysis of the
PEG-(C34)HSA derivatives also indicated negligible changes in secondary protein
structure relative to n-HSA, with very minor perturbations in 195−260 nm region (Figure
4.2). We thus presume that S-PEGylation at Cys-34 has minimal influence on the
secondary structure of HSA.

Figure 4.2. Circular dichroism spectra of n-HSA, PEG5K(C34)HSA (72% conversion),
and PEG20K(C34)HSA (77% conversion).

Effect of PTX‒HSA Formulations on Cell Viability
MCF-7 cells exposed to 10 nM PTX using a 30:1 mole ratio of PTX:n-HSA had
a 1.7-fold greater therapeutic effect compared to 10 nM PTX in PBS without HSA (p <
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0.05), whereas PTX formulated in a 10:1 mole ratio with n-HSA had 3.1-fold greater
efficacy (p < 0.005; Figure 4.3).45 HSA without PTX (up to 100 nM) had a negligible
effect on cell viability, confirming that its primary role is to increase the solubilization of
PTX. The increased drug efficacy did not vary significantly for PTX:n-HSA ratios below
10:1, implying an upper limit of 10 molecules of PTX per HSA carrier.

Figure 4.3. The effect of formulating PTX (10 nM) with n-HSA on MCF-7 cell cultures, 5
days post-treatment (N=3). PTX:n-HSA mole ratios range from 30 to 0.1, with [PTX]
fixed at 10 nM. Significant changes in cytotoxicity marked with * (p < 0.05) or ** (p <
0.005). Error = 1 stdev.

MCF-7 cells exposed to 10 nM PTX in a 10:1 mole ratio of PTX and
PEG5K(C34)HSA or PEG20K(C34)HSA experienced similar increases in toxicity relative
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to PTX alone (Figure 4.4). As in the case with n-HSA, maximum efficacy was attained
when PTX was formulated in a 10:1 mole ratio with PEG(C34)HSA derivatives
compared to a 30:1 ratio, with no further improvements below that. These results imply
that the PEG chain does not inhibit the ability of HSA to bind and release PTX. Again,
control experiments indicated that PEGylated HSA derivatives have no effect on cell
viability.
MCF-7 cells were exposed to a range of PTX doses (0.3
‒33 nM) formulated at
10:1 mole ratios with n-HSA, PEG5K(C34)HSA, or PEG20K(C34)HSA. For intermediate
PTX doses (6.6 nM), we observed that formulations with PEG20K(C34)HSA were at least
60% more toxic than that of PEG5K(C34)HSA (p<0.05), and 80% more toxic than that of
n-HSA (p < 0.01; Figure 4.5). A linear interpolation of cytotoxicity data at 3.3 and 6.6
nM yields IC50 values of 6.5, 5.9, and 4.7 nM when PTX is formulated respectively with
10 mol% of n-HSA, PEG5K(C34)HSA, and PEG20K(C34)HSA, with the latter providing a
nearly 40% increase in acute cytotoxicity relative to n-HSA. While the basis for the
greater potency provided by PEG20K(C34)HSA has not yet been elucidated, we observe
an intriguing correlation with changes in the self-association behavior of HSA induced by
Cys-34 tethered mPEG chains (see below).
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Figure 4.4. The effects of PTX (10 nM) formulated with PEG5K(C34)HSA or
PEG20K(C34)HSA on MCF-7 cell cultures, 5 days post-treatment, with [PTX] fixed at 10
nM (PTX:HSA = 30‒0.1; N=3). Significant changes in cytotoxicity marked with * and **
(p < 0.005). Error = 1 stdev.

Figure 4.5. Cytotoxicity of PTX (0.3‒33 nM) formulated in a 10:1 mole ratio with n-HSA,
PEG5K(C34)HSA, or PEG20K(C34)HSA (MCF-7 cells, 5 days post-treatment; N=3).
Significant changes in cytotoxicity marked with * (p < 0.05) or ** (p < 0.01). Error = 1
stdev.
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Effects of PEGylation and PTX on Protein Nanoparticle Formation
Nanoparticle tracking analysis (NTA) was used to measure the hydrodynamic size
(dh) and concentration of submicron protein aggregates in PBS (pH 6.5). In nearly all
cases, multimodal distributions were obtained with a wide variance (range of 100‒400
nm); however, a comparison between datasets revealed clear differences in population
sizes. At high protein concentration (1 mg/mL or
‒1513µM), mixtures containing
PEG5K- and PEG20K(C34)HSA formed several times more nanoparticles than n-HSA
(Figure 4.6a), while their dh and volumetric mean values (dvol) remained roughly the same
(Table 4.1). At tenfold lower concentration (0.1 mg/mL or ‒1.5
1.3 µM), suspensions
with PEGylated HSA again showed a higher number of nano-aggregates relative to pure
n-HSA (Figure 4.6b). Although these concentrations are substantially higher than those
used in the cytotoxicity assays, they show that S-PEGylation promotes HSA nanoparticle
formation. It is worth noting that dynamic light scattering analysis of PEG20K(C34)HSA
at 0.01 mg/mL also indicates nanoparticle formation (dh = 30‒80 nm), whereas n-HSA at
the same concentration is essentially monomeric.36
The effects of PEGylation on the spontaneous formation of HSA nanoparticles
were also evident for excipients formulated with PTX at a 10:1 mole ratio. At low carrier
concentration (0.1 mg/mL), mixtures with PEG5K- and PEG20K(C34)HSA formed
aggregates with a narrower, bimodal distribution relative to n-HSA (Figure 4.6c).46 It is
worth noting that the number of n-HSA and PEG20K(C34)HSA nanoparticles increased
significantly in the presence of PTX, suggesting their formation to be driven partly by the
cooperative association of hydrophobic domains. These results reveal the complex
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interplay between protein concentration, PEG chain length, and the inclusion of PTX on
the self-assembly of HSA nanoparticles in physiologically relevant conditions.

Table 4.1. Statistical analysis of HSA nanoparticles by NTA.
particle count
6
(× 10 mL-1)a

Sample

hydrodynamic size (nm)
mode peaks b

mean (dh) RSD (%)

dvol c RSD (%)

1 mg/mL (no PTX)
n-HSA

258

100‒160
(broad), 235

162

48

200

43

mPEG5K(C34)HSA

745

100, 320

152

51

195

45

mPEG20K(C34)HSA

671

140, 220

188

50

237

45

n-HSA

92

120, 150, 225,
340

192

37

219

35

mPEG5K(C34)HSA

221

125, 210, 290

166

48

206

43

mPEG20K(C34)HSA

157

120, 180, 290

182

48

227

44

n-HSA

123

90, 140, 220

189

65

264

54

mPEG5K(C34)HSA

161

90, 160

105

35

120

33

mPEG20K(C34)HSA

225

105, 210

141

43

173

40

215

110, 160, 310

173

38

198

35

0.1 mg/mL (no PTX)

0.1 mg/mL (10:1 PTX:HSA)

d

PTX, 13 µg/mL
a

Based on average number of tracks over three runs. b >100% above background. c Volumetric mean dvol =

(Σnidi3/N)1/3, where ni is the number of particles with size di.
HSA present.

d

15 µM PTX with 1% DMSO in PBS; no
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a

b

c

Figure 4.6. Hydrodynamic size analysis and number distribution of HSA nanoparticles by
NTA, for mixtures comprised of n-HSA, PEG5K(C34)HSA, and PEG20K(C34)HSA in PBS.
(a) 1 mg/mL (13‒15 µM), (b) 0.1 mg/mL (1.3‒1.5 µM), (c) 0.1 mg/mL with 10 equiv.
PTX. A plot of PTX aggregates in PBS without HSA ([PTX] = 12.5 µM) is included for
comparison.44
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Effect of Formulations on PTX Permeability
Monolayers of HUVEC and hCMEC/D3 cells were initially tested to examine the
effect of n-HSA and mPEG(C34)HSA on PTX permeability, using [14C]-labeled drug.
HUVEC monolayers are used to model the peripheral vasculature, whereas the
hCMEC/D3 monolayers are representative of the blood‒brain barrier.

47,48

Studies were

run at 1 μM [14C]-PTX alone and in 10:1 mole ratio with n-HSA or mPEG(C34)HSA,
preceded by a 4-hour pre-equilibration period for the cell monolayers (Figure 4.7).49 The
HSA formulations did not produce significant differences in [14C]-PTX permeation
across either cell monolayer, which suggests that the binding and permeation of free PTX
may be reversible. However, HUVEC monolayers exhibited significantly faster
permeability rates, implying that PTX permeates more readily into the vascular periphery
relative to the brain. This is expected, as hCMEC/D3 cells express high levels of efflux
transporters such as P-glycoprotein that are active against PTX.50

112

Apparent Permeability (cm/s)

9.0E-06
8.0E-06
7.0E-06

PTX Alone
Native HSA
HSA-PEG 5K
HSA-PEG 20K

6.0E-06
5.0E-06
4.0E-06
3.0E-06
2.0E-06
1.0E-06
0.0E+00

hCEMC/D3

HUVEC

Figure 4.7. Permeability of 1 μM [14C]-paclitaxel across hCMEC/D3 and HUVEC
monolayers. Studies were run in triplicate simultaneously using a 10:1 mole ratio of
PTX:n-HSA or PEG(C34)HSA (error = 1 stdev).

The effect of PTX concentration on HSA-mediated permeability was also
investigated. Papp values across HUVEC monolayers were initially obtained at 0.5, 1, 10,
and 25 μM PTX in a 10:1 mole ratio with n-HSA or PEG(C34)HSA, following preequilibration. Studies conducted at 0.5 and 1 μM PTX contained only [14C]-labeled drug,
whereas higher concentrations were made from unlabeled drug supplemented with 1 μM
[14C]PTX. At low solute concentrations, n-HSA appears to provide greater permeability
then either PEG5K(C34)HSA or PEG20K(C34)HSA, but at higher concentrations no
significant differences are observed (Figure 4.8a). The effect of drug
‒carrier ratio on
permeability was also examined at a 5:1 ratio of PTX to n-HSA or PEG(C34)-HSA
(Figure 4.8b). In this case, modest decreases in Papp values at higher solute concentrations
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were observed for all three HSA formulations, with minor differences between carrier
species.

a

1.4E-05

Papp (cm/sec)

1.2E-05
1.0E-05

*

** *
**

8.0E-06

*
*

6.0E-06

0.5 uM PTX
1 uM PTX
10 uM PTX
25 uM PTX

4.0E-06
2.0E-06
0.0E+00

nHSA

b

HSA-5k

HSA-20k

1.4E-05

Papp (cm/sec)

1.2E-05

* *

1.0E-05
8.0E-06

*

6.0E-06
4.0E-06
2.0E-06
0.0E+00

nHSA

HSA-5k

HSA-20k

Figure 4.8. Effect of solute concentration on HSA-mediated HUVEC permeability. (a)
Papp of [14C]-PTX using a 10:1 mole ratio of PTX to HSA carrier; (b) Papp of [14C]-PTX
using a 5:1 mole ratio of PTX to HSA carrier. Permeability studies were run in triplicate
simultaneously; differences between carriers marked with * (p < 0.05) or ** (p < 0.01).
Error = 1 stdev.

While Papp is useful for delineating possible changes due to partitioning,
diffusivity, or variations in free drug for each formulation, it only represents average
marker velocities. It is perhaps more important to consider the effects of formulation on
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drug flux (Papp × C0), which represents the actual amount of drug transferred across the
endothelial barrier and is a reliable metric for estimating blood levels. Since flux is
concentration-dependent, it better illustrates the effects of solubilizing formulations than
the relatively small changes in Papp. As expected, large increases in flux are observed for
both 10:1 and 5:1 mole ratios of PTX to n-HSA or its S-PEGylated conjugates (Figure
4.9). Again, S-PEGylation had little to no impact on drug transport, with minor
differences attributable to the limited precision typically observed in permeation studies.
This establishes that C34-PEGylated HSA can increase PTX efficacy as shown above,
without compromising drug solubilization and permeability.
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a

0.5 uM PTX
1 uM PTX
10 uM PTX
25 uM PTX

220
200

Flux (pg/cm2.sec)

180
160
140
120
100

*

*

80
60
40
20

**

0

nHSA

b

* *

**

HSA-5k

HSA-20k

220
200

Flux (pg/cm2.sec)

180
160
140
120
100
80

*

60
40

* *

20
0

nHSA

HSA-5k

HSA-20k

Figure 4.9. [14C]-PTX flux through HUVEC monolayers using n-HSA or PEG(C34)HSA.
(a) 10:1 molar ratio of PTX to HSA carrier; (b) 5:1 molar ratio of PTX to HSA carrier.
Permeability studies run in triplicate simultaneously; differences between carriers
marked with * (p < 0.05) or ** (p < 0.01). Error = 1 stdev.

The enhanced efficacy of PTX formulated with PEG5K- and especially
PEG20K(C34)HSA is greatest near its IC50 value against MCF-7 breast cancer cells. We
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also observe that S-PEGylation increases the number of HSA nanoparticles (up to 1.8fold) relative to n-HSA, particularly in the presence of PTX. While further research is
needed to establish the basis for therapeutic enhancement, we consider the following as
plausible factors for the observed phenomena:
1. While the 5- and 20-kDa PEG chain attached to Cys-34 do not disrupt the tertiary
structure of HSA, they may reduce its strength of association with bound PTX by
increasing its conformational lability;
2. Changes in the conformational stability of S-PEGylated HSA may also affect the
stability of their aggregates in endosomes, with greater PTX release to the
cytoplasm after uptake;
3. The PEG chains may promote the nano-emulsification of HSA and PTX,46 into
forms that are favorably transported by albumin receptors.
In short, while the prescribed benefits of protein PEGylation such as extended
stability and circulation times in the bloodstream are well appreciated,12-15 there appear to
be additional factors that may contribute toward favorable pharmacokinetics and drug
release profiles, and await further validation.

4.4

Conclusions

We have established that formulation of PTX with PEG5K(C34)HSA and
especially PEG20K(C34)HSA enhances its acute toxicity against MCF-7 breast cancer
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cells relative to native HSA carriers, while retaining high levels of permeability across
monolayers of HUVEC or hCMEC/D3 cells. The latter has important ramifications on
the bioavailability of PTX administered by non-intravenous mechanisms, as well as its
extravasation into diseased tissue. C34-PEGylation has a notable influence on the size
distribution of HSA nanoparticles, which may be partly responsible for the increased
cytotoxicity of the PTX payload.51 Future studies are needed to generalize the therapeutic
and pharmacokinetic enhancements of PEG(C34)HSA-mediated uptake for different
classes of hydrophobic drugs, as well as various cancer cell lines and animal tumor
models.
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CHAPTER 5. CHARACTERIZATION, FORMULATION, &
PRECLINICAL ASSESSMENT OF AN ANTIVIRAL V-ATPASE
INHIBITOR, SALIPHENYLHALAMIDE

5.1.

Introduction
The 2014 Ebola outbreaks in West Africa have reinforced the concerns over high

mortality and morbidity associated with pathogenic epidemics, particularly with yet
unmet therapeutic viral entities.1 This outbreak was just the most recent in a number of
outbreaks worldwide caused by a number of different infectious pathogens.

These

outbreaks also lead to significant concerns about the potential of infectious pathogens to
be weaponized and to be utilized in warfare.2 Thus, there has been an urgent need placed
on the search for therapeutic agents that may serve as countermeasures to mitigate
pathogenic agents exploited for terror or warfare applications. In addition to Ebola, a
number of other viral pathogens have been identified as high risk agents for
weaponization and potential use in malicious manners including the encephalitic
alphaviruses including the Venezuelan (VEEV), Eastern Equine (EEEV) and Western
Equine (WEEV) encephalitic viruses.2 Universal to many of these high morbidity and
mortality associated viruses is that their disease inducing pathogenesis relies on the host
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cell entry and intracellular trafficking via endocytosis and subsequent activation within
the endolysosomal compartments.3,4
The combined research efforts of the investigative team have been focused on the
development of an agent known to inhibit a critical protein, Vacuolar-ATPase (VATPase) that acidifies the endolysosomal vesicles and activates the virus. Briefly, the VATPase is a proton transporter which utilizes ATP to move protons against a
concentration gradient into vesicles within the cell, resulting in reduction of pH within
the vesicle.3 This low pH leads to a cascade of enzymatic activity and formation of the
lysosome. However, for many viruses, this low pH is necessary to trigger membrane
fusion, unloading of viral RNA, and replication after endocytosis.4 We have investigated
the development of saliphenylhalamide (SaliPhe), a potent analog of salicylihalamide that
is a natural product known to act as a V-ATPase inhibitor.5,6 Therefore,
salipenylhalamide may be effective at stopping replication of many viruses that utilize
this mechanism to trigger unfolding. It should also be noted that V-ATPase inhibition is
currently also being investigated for treatment of osteoporosis and cancer.5-7

While there has been some investigation into in vitro and in vivo efficacy of
SaliPhe, less research has been conducted into its physicochemical properties,
pharmacokinetics, and overall druggability. With a molecular weight of 459.5, SaliPhe is
under the 500 MW cutoff often associated with steep drop-offs in uptake and permeation
rates that increase intracellular accumulation and drug distribution.8 In addition, it’s
predicted polar surface area is only 96 Å2¸which is well below the cutoff of 140 Å2 for
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peripheral permeation and just over the cutoff for uptake into the brain 90 Å2.9 SaliPhe
has an AlogP of 4.5, which, while at the high end, is within the druggable range for
pharmaceutical compounds. Favorably, this high AlogP may also lead to increased
distribution into the brain.10
solubility related.

Current limitations with SaliPhe are predicted to be

In vivo efficacy studies suggest 7 mg/kg to be the efficacious

intraperitoneal dose.11 With a predicted solubility of 0.2 μg/mL at physiological pH, the
drug is unlikely to reach efficacious levels without an exposure enhancing formulation.

Here we look to elucidate the relevant physicochemical properties of SaliPhe and
to utilize these properties to guide formulation development. Formulations with enabling
properties were screened on in vitro cell models to assess changes in permeability and
cytotoxicity.

Finally, testing was conducted on promising formulations for

pharmacokinetics, biodistribution, toxicity, and efficacy in murine models. In addition,
we proposed to characterize the physicochemical properties of structurally related
SaliPhe analogs that were being developed to overcome several SaliPhe limitations for
therapeutic utilization.

SaliPhe has been previously investigated for other chronic

indications, although the drug was not advanced to the market due to druggability and
toxicity concerns.11 These analogs may allow for safe and efficacious acute use of the
drug, minimizing the challenges associated with chronic SaliPhe therapy.

129
The tasks that were conducted at Purdue included:
1. SaliPhe ADME/T Assays
2. Performance of Physicochemical and Preformulation Studies and
3. Plasma PK for 3-5 formulation/prodrugs in rats and biodistribution in mice for
2 formulations/prodrugs. Note: Biodistribution studies were conducted in
conjunction with the University of Louisville to ensure that the same mice that
the efficacy studies were performed in were used to measure distribution.

Initially we began early analysis to perform physicochemical analysis then made
stable, solubility enabling formulations followed by investigation of the permeability of
SaliPhe, and associated analogs, alone and in formulations across in vitro barriers of
relevant cell models. This included human epithelial colorectal adenocarcinoma cells
(Caco-2),12-14 human umbilical vein endothelial cells (HUVEC),15 hCMEC/D3 (human
cerebral microvascular endothelial cell),16-19 and novel direct coculture and triculture in
vitro models of the blood brain barrier (BBB) recently developed in the Knipp laboratory.

In latter studies, two formulations of SaliPhe and one of a SaliPhe prodrug were
submitted for rat PK analysis. In addition, one biodistribution study was performed at
Louisville and the organs were collected and submitted for bioanalysis at the Purdue
Metabolite Profiling Facility. The methodology, results and a discussion of findings is
presented below.
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5.2.

Materials and Methods

Materials
Poloxamer 407, Poloxamer 188, Kolliphor EL, Kolliphor RH 40, Kolliphor HS
15, Kollidon 25, Kollisolv PEG E 400, propylene glycol, hydroxpropyl-β-cyclodextrin,
tween 80, d-alpha tocopheryl polyethylene glycol 1000 succinate, acetonitrile, Hank’s
balanced salt solution (HBSS), phosphate buffered saline (PBS), Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum, penicillin-streptomycin, non-essential
amino acids, L-glutamine, hydrocortisone, type I rat tail collagen, polystyrene T-75
flasks, and Transwell permeable supports were purchased from Sigma-Aldrich (St.
Louis, MO). EGM-2, EBM-2, and basic fibroblast growth factor were obtained from
Lonza (Walkersville, MD). Chemically defined lipid concentrate was purchased from
LifeTechnologies (Carlsbad, CA). Human astrocytes, human pericytes, astrocyte
medium, and pericytes medium was purchased from ScienCell (Carlsbad, CA). Caco-2
and HUVEC cells were obtained from the American Type Culture Collection (ATCC;
Manassas, VA); hCMEC/D3 cells were provided by Dr. Pierre-Olivier Couraud at Institut
Cochin (Paris, France). Labrasol and Labrafil M 1944 CS were donated by Gattefosse,
(Saint-Priest, France).
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Methods
HPLC Analysis
HPLC-Samples were run on an Agilent 1100 HPLC.

A 1.5 mL/min 50:50

Acetonitrile:Water isocratic method was used for 10 minutes with a retention time of 6.9
minutes. An Agilent Eclipse XDB-C18, 5 μm, 4.6 x 150mm column with Security
Guard-C18, 4 x3.0mm guard column was kept at 40oC. UV detection was at 280 nm.
Injections of SaliPhe alone were 100 μL/sample, formulated samples were 5 μL/sample.

Powder X-ray Diffraction
To assess crystallinity of the SaliPhe received, approximately 30mg was used for
testing with Powder X-ray Diffraction (PXRD) on a Rigaku SmartLab XRD system.
Sample was added onto a sample holder and gently crushed and flattened. Intensity was
then measured from 5 to 40 degrees (2θ). Step size was 0.02 degrees at a speed of 40
θ/minute. Voltage and current used were 40mV and 44mA respectively.

Differential Scanning Calorimetry
Thermal analysis was conducted on a TA Instruments Q1000 to confirm PXRD
results and establish a melting point. 2.5 mg of sample was first hermetically sealed into
an aluminum pan. Changes in heat flow were measured from 25-350oC at a rate of
10oC/minute. N2 was used as a purging gas and indium was used for calibration.
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Octanol:Water Partition Coefficient
Approximation of LogD was conducted in 0.1N HCl, (~pH 1), 10μM Acetate
Buffer pH 4.5, and pH 7.4 PBS. Prior to studies, 50mL of each aqueous solution was
equilibrated with 50mL 1-octanol for 24 hours. Approximately 1mg SaliPhe was then
added to 500μL of each of the pre-equilibrated 1-octanol solutions. After dissolution of
the SaliPhe, 500uL of pre-equilibrated aqueous buffer was added and vortexed for 2
minutes. Samples were allowed to equilibrate overnight before samples from each phase
were run according the HPLC method above with 1-octanol samples diluted 50 times in
DMSO. LogD was calculated by taking:

LogD = log (

[𝑆𝑎𝑙𝑖𝑃ℎ𝑒1−𝑜𝑐𝑡𝑎𝑛𝑜𝑙 ]

�𝑆𝑎𝑙𝑖𝑃ℎ𝑒𝐴𝑞𝑢𝑒𝑜𝑢𝑠 𝐵𝑢𝑓𝑓𝑒𝑟 �

)

Polymer Formulation Solubility Assessment
To estimate solubility in a number of polymer solutions, 10% solutions were first
made up by heating reagents to 50oC on a hotplate and incorporation by vortexing for up
to 15 minutes. SaliPhe in 100% DMSO was then spiked into each of the polymer
solutions and vortexed for 5 minutes. Following vortexing, samples were allowed to
equilibrate for 90 minutes followed by a 15 minute centrifuge at 13,000 RPM. The
supernatant was then removed and evaluated on the HPLC as described above.
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Polymer Formulation Stability
Stability of formulations which lead to satisfactory increases in solubility were
further characterized based on stability. Samples were stored at 0, 25, and 37oC for one
week in silanized inserts. Samples were taken multiple times on the first day followed by
once each additional day Stability was estimated based on changes in AUC after triplicate
injection according to the HPLC method above. Before each sample was run, silanized
inserts were centrifuged at 13,000 RPM for 15 minutes and supernatant was removed.
Additional stability studies were conducted for SaliPhe alone in 0.1N HCl, pH 4.5 10mM
acetate buffer, and PBS.

Emulsion Formulation
An emulsion formulation was made as an alternative dosing strategy for SaliPhe.
Emulsion formulations were kept simple with a single aqueous phase (PBS), oil phase
(Labrafil or Capryol), and surfactant (Solutol HS 15, Cremophor EL, Lecithin,
Transcutol, Labrasol, Propylene Glycol).

Emulsions were made by first dissolving

SaliPhe into the oil phase. The surfactant(s) were then added and vortexed for 1 minute.
PBS was then added to the oil/surfactant and again vortexed for 1 minute. Vortexing was
followed by microtip sonication for 1 minute. The sample was then vortexed until
homogeneous. Formulations were then assessed based on translucence which was used
to determine the ability of the formulation to both solubilize SaliPhe and form an
emulsion. Next, the formulations were left for 5 days at room temperature to assess the
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physical stability. Additional physical stability was conducted through an overnight
freeze and thaw. Finally, viscosity was assessed at room temperature. It was determined
through consolation with animal care that solutions more viscous than propylene glycol
may be lethal to the rodents in pre-clinical studies, therefore, only those that were
significantly less viscous by eye were used for further testing according to the Purdue
Animal Care and Use Committee (PACUC) and the approved ACURO form that was
submitted.

Cell Culture
Caco-2 cells were cultured in DMEM supplemented with 10% FBS, penicillinstreptomycin, L-glutamine, and non-essential amino acids. While culture flasks were not
prepped, Transwells were coated with 65μL/well of 1mg/mL type I rat tail collagen in
60% ethanol and left to evaporate for at least 4 hours. Caco-2 cells were seeded at
75,000 cells/cm2 and grown for 21-28 days before permeability studies were conducted.
Human Umbilical Vascular Endothelial cells (HUVEC), mimicking the peripheral
vasculature for organ distribution, were cultured in EBM-2 supplemented with EGM-2
bulletkits. HUVEC flasks were precoated with 1 μg/cm2 fibronectin. Transwells were
coated with 65μL/well of 1mg/mL type I rat tail collagen in 60% ethanol and left to
evaporate for at least 4 hours. HUVEC cells were seeded at 50,000 cells/cm2 and left to
proliferate/differentiate for 7 days prior to studies.
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hCMEC/D3 cells were cultured in EBM-2 supplemented with 5% FBS, basic
fibroblast growth factor, chemically defined lipid concentrate, HEPES buffer, ascorbic
acid, penicillin streptomycin, and hydrocortisone. hCMEC/D3 flasks were precoated
with 6 mL of 150μg/mL of type I rat tail collagen in water. Transwells were coated with
65μL/well of 1mg/mL type I rat tail collagen in 60% ethanol and left to evaporate for at
least 4 hours. hCMEC/D3 cells were seeded at 100,000 cells/cm2 and grown for 7 days
before studies.
Human astrocytes were grown in ScienCell’s complete astrocyte medium. Flasks
were coated as recommended with 2 μg/cm2 Poly-L-Lysine. Transwells were coated with
5 μg/cm2 to promote proliferation and differentiation. Astrocytes were seeded at 40,000
cells/cm2 and grown 2 days before culture with additional cell lines. Human Pericytes
were grown in a similar fashion with the exception of utilization of ScienCell’s complete
pericyte medium.
For hCMEC/D3 and human astrocyte coculture studies, human astrocytes were
first plated as discussed above. After two days in astrocyte medium, hCMEC/D3s were
seeded directly on top of the astrocytes and grown for 7 days in hCMEC/D3
supplemented EBM-2 before studies.

For triculture studies, 40,000 human

astrocytes/cm2 were seeded in astrocyte media onto Transwells® (Corning-Costar) pretreated with 5μg/cm2 Poly-L-Lysine and grown for 2 days. An additional 1 μg/cm2 PolyL-Lysine was then added to the top of the astrocytes followed by pericytes at a density of
40,000 cells/cm2. After two additional days of growth, 15 μg/cm2 type I rat tail collagen
was added followed by 80,000 hCMEC/D3 cells/cm2. The triculture was grown for 7
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more days with hCMEC/D3 supplemented EBM-2 in the apical compartment and
astrocyte medium in the basolateral compartment before permeability studies were
conducted. It should be noted that the culture conditions were optimized under separate
studies in our laboratory and have been disclosed via a provisional patent application.

All cells were grown in 5% CO2, 37oC, and 95% RH. Passages were conducted
between 80 and 90% confluence. Cells were limited to passage 50 for Caco-2s, passage
12 for HUVECs, passage 45 for hCMEC/D3s, passage 15 for human astrocytes, and
passage 12 for human pericytes.

Permeability Studies
All permeability studies were conducted statically in triplicate on 0.4μm
polyethylene 12-well Transwell supports. Prior to studies, media was removed and cells
were washed twice with PBS. Cells were subsequently equilibrated in HBSS for at least
20 minutes. SaliPhe solutions were then added to the donor compartment. Receiver
compartments contained vehicle used in donor. Samples were taken at 30, 60, 120, and
180 minutes as well as donor C0 and C180 minutes samples. 200μL samples were taken from
basolateral compartment while only 100 μL samples were taken from the apical
compartment. Sample volume was replaced with blank vehicle after each time point, and
the lost mass was accounted for in the permeability calculation. Samples were run on
HPLC according to method above with 100 μL injections for receiver compartment
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samples, 50 μL for donor compartment samples, 100 μL injections for SaliPhe alone C0,
and 5 μL for solubility enabled formulation C0. Permeability coefficients (cm/s) were
obtained through the following equation:

where

𝑑𝑀
𝑑𝑡

𝑃𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡

𝑑𝑀
𝑑𝑡
=
𝐶0 ∗ 𝑆𝐴 ∗ 60

is the rate of SaliPhe or prodrug transfer across the cell layer, 𝐶0 is the initial

donor concentration, and 𝑆𝐴 is the surface area of the Transwell® filter support and 60
converts units in cm/min to cm/s.

In Vivo Rat PK Studies
Pre-clinical rat PK studies were conducted according to the Purdue Animal Care
and Use Committee (PACUC) and the approved ACURO submitted protocols with two
SaliPhe formulations (3.5mg/mL SaliPhe in 2% P407 and in the F22 emulsion) as well as
OM510 in 2% P407. Studies were conducted on rats of approximately 250g and utilized
the BASi Culex-S “Rat-Turn” model. Samples were analyzed by LC-MS/MS utilizing
optimized protocols through the Purdue Metabolite Profiling facility, as we have utilized
previously.20-22

Noncompartmental pharmacokinetic data analysis was performed using PK
Solutions 2.0 from Summit Research Services (Montrose, CO). SaliPhe or OM510
plasma concentration time data were input into the software and the resultant profiles
were curve stripped to extract the PK parameters. SaliPhe or OM510 plasma
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concentrations below the limit of quantitation were set to zero for determination of PK
parameters.

5.3.

Results and Discussion

Powder X-Ray Diffraction (PXRD)
PXRD was run on the samples to assess crystallinity of the SaliPhe batch samples
obtained.

The sample appeared to be mostly amorphous as evidenced by a large

amorphous halo. However, small amounts of crystallinity may be indicated by small
peaks in intensity, specifically around 18 degrees. Due to concerns for material usage,
replicates were not performed and confirmation of crystalinity was attempted by DSC.
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Figure 5.1. Powder x-ray diffraction of Saliphenylhalamide.
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Differential Scanning Calorimetry (DSC)
The DSC shows a small endotherm at 110oC suggesting some crystallinity may be
present and is melting, which could confirm the PXRD measurement. However, it is also
possible that desolvation of a residual solvent may be occurring. This is followed by
degradation at approximately 220oC. Additional melts between 160oC and 210oC are
speculated to be either small amounts of impurities or traces of potential enantiotropicly
more stable polymorphs are formed and then melting.

Hot stage microscopy,

thermogravimetric analysis, and potential variable temperature PXRD are recommended
for future batch characterizations to decipher the nature of these transitions.
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Figure 5.2. Differential scanning calorimetry of Saliphenylhalamide.
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LogD
Log D values were relatively unchanged across the various aqueous conditions
with a pH range spanning between ~1 and 7.4, when assessed in 0.1N HCl, pH 4.5
acetate buffer, and pH 7.4 PBS. In addition, values between 4.64 and 4.76 suggest a
highly lipophillic compound at physiological pHs found in the blood and along the
gastrointestinal (GI) tract. However, while high, it is in the druggable range suggested by
Lipinski’s “Rule of 5”. Conversely, these Log D’s lie outside the druggable range
suggested by GSK’s 4/400 rule and Pfizer’s 3/75 rule which may indicate poor
druggability and an increased toxicological risk respectively.23 One benefit of the high
LogD is the potential for increased uptake into the brain which may be necessary for
targeting encephalitic viruses like VEEV.9

LogD
5.00

4.76

4.75

4.64

0.1N HCl

Acetate pH 4.5

PBS

4.00
3.00
2.00
1.00
0.00

Figure 5.3. LogD values of Saliphenylhalamide. Samples performed in triplicate, error
bars represent 1 standard deviation.
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Polymer-Based Solubility Enhancement
As suggested above, the solubility of SaliPhe may be rate limiting in its
druggability.15,23,24 In order to potentially improve solubility through polymer
complexation, a number of excipients were examined.

It was determined that for

exposure enabled pre-clinical formulations, a formulation solubility of at least 875 μg/mL
would be necessary. Initial studies investigated solubilizing ability of 10% polymer.
Table 5.1. Solubility of Saliphenyhalamide in 10% polymer or excipient solutions.
Polymer

Solubility in 10% w/w Polymer:HBSS
(μg/mL)

Kolliphor EL

664

Kollidon 25

194

Kolliphor RH 40

>4000

Poloxamer 407

>4000

Kolliphor HS 15

3580

Tween 80

3290

Kollisolv PEG E 400

18

Vitamin E TPGS

3780

Propylene Glycol

11

Poloxamer 188

24

Hydroxypropyl-β-Cyclodextrin

24

HBSS

5.3

50:50 ACN:Water

>4000
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This study was able to eliminate several potential GRAS and Pharmaceutical
R&D approved excipients from further utilization. We selected several other excipients
based on their ability to generate a 4 mg/mL solution. Minimization of excipient choices
enabled a reduction in polymer excipient concentration and potential confounding
polymer effects. The maximum solubility at 1% of the remaining polymers was then
determined.

Table 5.2. Solubility of Saliphenylhalamide in 1% polymer solutions.
Polymer

Solubility in 1% w/w Polymer:HBSS (μg/mL)

Kolliphor RH 40

2260

Kolliphor HS 15

200

Poloxamer 407

2270

TPGS

1060

Tween 80

910

This study suggests that SaliPhe is most soluble in Kolliphor RH 40 and
Poloxamer 407. Poloxamer 407 was selected for further studies as it is much easier to
handle and holds a stable solubility at 4oC, which would be important for storage of stock
solutions. Upon permeability testing in HUVEC cells, we did observe reduced
permeability coefficients across for SaliPhe when formulated with P407 as opposed to
RH40. We hypothesize that this may be due to polymer binding.
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HUVEC Permeability
Apparent Permeability (cm/s)

3.50E-06
3.00E-06
2.50E-06
2.00E-06
1.50E-06
1.00E-06
5.00E-07
0.00E+00
1% P407

5% P407

1% RH 40

5% RH 40

Figure 5.4. Apparent HUVEC permeability of 100ug/mL Saliphenylhalamide in 1 and 5%
P407 and RH 40 formulations. Studies were run in triplicate with error bars
representing 1 standard deviation.

Upon re-evaluation, we wanted to ensure that sufficient solubility of SaliPhe was
maintained, thus we decided to use a 2% P407 solution for IP injection. As a 500 μL
injection is the maximum allowable injection for the rats, a 7 mg/kg dose required
solubility of 3.5 mg/mL. This was achievable with both 2% and 5% P407. A preliminary
study conducted at the University of Louisville revealed that the 5% P407 may have
potential adverse effects in rodents that were not observed with the 2% concentration.
While manufacturer recommendations suggest 5% P407 formulations to be safe in
rodents, we selected 2% to ensure solubilization and to minimize potential adverse
outcomes.
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Stability of Polymer-Based Solubility Enhancing Formulation
Similar to known stability issues of SaliPhe in acid, considerable degradation of
P407 formulated SaliPhe still occurs. Approximately 40% of the drug degrades in the
first hour in 0.1N HCl. It is unknown if further enzymatic degradation may occur in the
stomach, however, the effect of pH alone may require co-administration with a basic
buffer, or enteric coating for oral delivery. These results reinforced our focusing on the
IP and IV administration routes and revealed that the peroral administration route was not
feasible in these early proof-of-concept studies.

SaliPhe in 5% Kolliphor P407 Acid Degradation
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Figure 5.5. Acid degradation of Saliphenyhalamide in 2% P407 formulation.

Further investigations were conducted to determine the stability of SaliPhe in rat
plasma, as the rodent Culex® units collect blood samples overnight and maintain them at
4ºC until processing and storage at -80 ºC. A 3.5 mg/mL 2% P407 formulation was
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diluted 50-fold into rat plasma and allowed to equilibrate for a number of different time
points. A marked drop in concentration (~50%) was seen after allowing the samples to
equilibrate for 1 hour, however, it then held concentration for over 24 hours.

We

hypothesized that this is due to binding of SaliPhe to serum proteins in the plasma. A
follow-up study revealed that an increased concentration of SaliPhe was obtained after an
acetonitrile precipitation prior to analysis in the presence of plasma proteins. Other than
plasma protein association, SaliPhe was determined to be stable in rat plasma. We
accounted for this loss in PK studies.

SaliPhe in 2% Kolliphor P407 Rat Plasma Stability
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Figure 5.6. Plasma degradation of Saliphenylhalamide in 2% P407 formulation.

Kolliphor P407 Permeability Studies
Due to the combined issues of solubility enhancement, safety, and stability, a
liquid formulation of 3.5 mg/mL of SaliPhe in 2% Kolliphor P407 was selected for
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further preclinical investigation. Initial studies were conducted on in vitro cell models to
elucidate potential deposition as well as changes in permeability upon dilution.

Caco-2 (human epithelial colorectal adenocarcinoma cells)
Initial permeability studies were conducted in Caco-2 cells to assess the
permeability of SaliPhe across a gastrointestinal (GI) barrier. SaliPhe was added at 3,
87.5, and 175 μg/mL for solubility enhanced formulations and 3 μg/mL for SaliPhe
alone. 87.5 and 175 μg/mL were selected to mimic dilution into the blood, while 3
μg/mL was run in 2% P407 and alone in HBSS to assess the effects of the formulation on

Apparent Permeability (cm/s)

permeability.

3.5E-07
3.0E-07
2.5E-07
2.0E-07
1.5E-07
1.0E-07
5.0E-08
0.0E+00
3ugmL in HBSS

3ugmL in
2%P407

87.5ugmL in
2%P407

175ugmL in
2%P407

Figure 5.7. Apparent Caco-2 permeability of unformulated Saliphenylhalamide and in
2%P407 formulation. Studies were run in triplicate with error bars representing 1
standard deviation.
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As can be seen in the figure above, it appears that the formulation does present a
significant reduction in permeation rates, most likely due to SaliPhe binding with P407
and minimizing the concentration of free drug that can readily permeate.

This

phenomena has been observed in other systems, particularly with amorphous
dispersions.24 Interestingly, at higher concentration of drug in P407, this effect wasn’t
seen and in fact, the permeability coefficients at these higher concentrations was
increased. As oral dosing of SaliPhe is currently unlikely, no further examination was
done.

HUVEC (human umbilical vein endothelial cells)
As SaliPhe is most likely to be dosed IV or IP, the permeability was measured
across the HUVEC cell line, which is often used as a representative cell line for the
peripheral capillaries, was assessed with the same formulations utilized in the Caco-2 cell
line. However, differences in permeability and permeation trends were seen. First,
permeability rates for SaliPhe through the HUVEC cell line was significantly faster than
Caco-2 permeability (around 10-fold).

In addition, in the HUVEC cells, increased

amounts of drug in the formulation didn’t seem to change the permeability of SaliPhe,
and if anything led to decreases.

In fact the P407 formulations lead to reduced

permeability across the HUVECs when compared to drug alone. We hypothesize that the
kinetics of binding with P407 may minimize the free drug concentration available for
permeation. We also caution that in vitro permeation rates are a guide and not reflective
of in vivo conditions.

Apparent Permeability (cm/s)
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Figure 5.8. Apparent HUVEC permeability of unformulated Saliphenylhalamide and in
2%P407 formulation. Studies were run in triplicate with error bars representing 1
standard deviation.

Blood-Brain Barrier Permeability
A number of studies were conducted to determine the permeability of SaliPhe
alone and in P407 formulations across BBB in vitro models. All models included the
hCMEC/D3 cell line, with coculture studies including direct contact culture with primary
human astrocytes and the triculture model grown in direct contact with both primary
human astrocytes and pericytes (IP Pending). Current work in the Knipp lab suggests the
co- and triculture models may serve as more physiologically relevant models for the in
vivo BBB screening (manuscripts in preparation). Studies were conducted at 5 μg/mL
SaliPhe alone and at 87.5, 175, and 437.5 μg/mL in 2% P407.

Apparent Permeability (cm/s)
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Figure 5.9. Apparent BBB permeability of unformulated Saliphenylhalamide and in
2%P407 formulation. Here, blue bars represent monoculture (hCMEC/D3 cells alone),
red bars represent coculture (hCMEC/D3 cells grown on Human Astrocyte lawn), and
green bars represent triculture (hCMEC/D3 cells grown on Human Astrocyte and
Human Pericyte lawn). Studies were run in triplicate with error bars representing 1
standard deviation.

The study again suggests a potential decrease in permeability in P407
formulations. In addition, a non-significant decrease in permeability was seen with
increased concentrations. Interestingly, permeability was highly variable between the
three models for studies of SaliPhe alone. Further investigation must be conducted to
determining the cause of this variability.

However, with the most physiologically

relevant BBB triculture model there appears to be little permeability change in relation to
concentration of SaliPhe or the presence of P407. In addition, the permeability across the
triculture is approximately 10-fold lower than in HUVEC cells, suggesting that
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disposition into the brain may be permeability-limited under normal physiological
conditions.

The in vivo BBB is disrupted in disease states from an inflammatory

response, thus the results suggest that the permeation across the normal BBB will be
reduced and may alleviate any potential off target effects that might arise.

Emulsion Formulation
A number of emulsion formulations were investigated as an additional means of
solubility enhancement and improving drug delivery. Formulations were selected based
on transparency, stability, viscosity, and their ability to solubilize 3 mg/mL SaliPhe.
Transparency was used as a criterion as it was the most rapid method to determine both
solubilization and micelle formation. In addition, high viscosity can result in animal
toxicity and potential death. Results of the formulation trails are shown below:
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Table 5.3. Saliphenylhalamide emulsion design of experiments. Here, values
represent percent of total formulation, Y implies yes formulation meets criteria, and N
implies no formulation does not meet criteria. Green represents a formulation passing all
criteria with red representing formulations failing one or more criteria.

Formulation #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

PBS
35
35
30
30
35
35
35
35
35
40
60
35
35
40
45
50
60
55
60
60
60
55
50
50

Labrafil
30

Capryol
30
30

30
30
30
30
30
40
35
10
30
30
20
20
20
20
20
15
15
15
15
15
15

% Total Formulation
Solutol Cremophor EL Lecithin Transcutol Labrasol Propylene Glycol
25
10
25
10
27
13
27
13
15
10
10
25
10
20
10
5
15
20
15
10
25
20
10
15
10
10
35
30
10
35
30
20
25
25
25
20
5
30
30
5
25
10

Stability
Y
N
N
N
Y
N
N
N
N
N
N
N
N
Y
Y
Y
Y
Y
Y
N
N
Y
Y
N

Comments
Clarity Fluidity Acceptability
Y
N
Y
Y
N
Y
Y/N
N
Y
Y
N
N
N
Y
Y
Y
N
Y
N
Y
Y
N
N
N
N
N
Y
Y
Y
Y
N
-

As can be seen, only formulations F16, F22, and F23 were able to meet all of the
criteria. After discussion with animal care, it was determined that viscosity for F16 and
F23 were high end and may cause some animal welfare concerns upon in vivo dosing.
Therefore, the lowest viscosity formulation, F22, was selected. This emulsion consisted
of 55% PBS, 15% Labrafil M 1944 CS, and 30% Solutol (Kolliphor HS15).
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In addition, the F22 micelles were analyzed by a Zetasizer to determine their size
and zeta-potential. As can be seen below, the micelles formed were relatively small with
a diameter of only 22 nm. This was unchanged when loaded with SaliPhe at 3 mg/mL.
Finally, the micelles both, blank and SaliPhe-loaded, showed a relatively neutral zetapotential. This may lead to stability concerns, however, samples were stable for >1 week.

Table 5.4. Characterization of blank and Saliphenylhalamide F22 emulsion formulations.

Properties
F22

Blank

SaliPhe-loaded

Size (d, nm)

22.12

23.13

Zeta potential (mV)

-2.06

-3.97

Emulsion Formulation Permeability Studies
Based on time constraints, permeability studies of SaliPhe in the F22 emulsion
were only measured across the HUVEC cell line to assess changes in the permeability
coefficients with the formulation. SaliPhe was run in F22 at 75, 150, and 300 μg/mL to
predict permeability at 10, 20, and 40-fold dilution into the blood and compared to 3
μg/mL SaliPhe alone. Below we see that formulation with F22 led to approximately 5fold reduction in permeability of SaliPhe. We hypothesize that this is likely due to the
inability of SaliPhe to permeate the HUVEC cells while sequestered in the emulsifying
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micelles. While further work is required, it also may indicate that systemic distribution
may be minimized based on the formulation in vivo.

Apparent Permeability (10-7 .cm/s)

80
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50
40
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0
3

30
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300

Concentration of SaliPhe (µg/mL)

Figure 5.10. Apparent HUVEC permeability of unformulated Saliphenylhalamide and in
F22 emulsion formulation. Studies were run in triplicate with error bars representing 1
standard deviation.

OM510 P407 Permeability Studies
Preliminary studies were conducted to determine the permeability of OM510 in
2% P407 across peripheral (HUVEC) and BBB (hCMEC/D3) cell models. Similar to
studies above, 2 μg/mL concentration represents drug alone, while the other
concentrations are representative of drug in 2% P407.
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Apparent Permeabilty (cm/s)

1.20E-05

hCMEC
HUVEC

1.00E-05
8.00E-06
6.00E-06
4.00E-06
2.00E-06
0.00E+00
2

10
50
Concentration of OM510 (µg/mL)

100

Figure 5.11. Apparent HUVEC and hCMEC/D3 monoculture permeability of
unformulated Saliphenylhalamide prodrug OM510 and in 2% P407 formulation. Here, 2
µg/mL samples represent unformulated while 10, 50, and 100 µg/mL samples are
formulated in 2% P407. Studies were run in triplicate with error bars representing 1
standard deviation.

These results suggest that OM510 permeability is much different than that of
SaliPhe. First, permeability of OM510 appears to be approximately 10-fold faster when
compared to SaliPhe. In addition, while the formulation with P407 shows similar reduced
HUVEC permeability when compared to SaliPhe, no reduction is seen with the
hCMEC/D3 cell line, which is similar to what was seen with the triculture model for
SaliPhe.
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Plasma Protein Binding
In order to determine potential protein binding, excess SaliPhe in DMSO was
added to a 1% (w/w) solution of Human Serum Albumin (HSA) in PBS. Samples were
allowed to equilibrate for 3 hours then centrifuged for 15 minutes at 15,000 RPM. The
supernatant was then diluted 2-fold in acetonitrile to crash out plasma protein. The
sample was again given 3 hours to equilibrate before being centrifuged as above. The
supernatant was then analyzed by HPLC. Results suggest that SaliPhe has a solubility of
approximately 100 μg/mL in a 1% HSA solution, almost 20-fold higher than that of PBS
alone.

This suggests SaliPhe may be highly protein bound in the plasma.

We

hypothesize that an HSA formulation may allow for extended delivery and increased
solubility in the blood. This an area of ongoing research in our laboratory.8

In Vivo Rat PK Studies
Finally, in order to determine the in vivo effects of SaliPhe formulation, three
formulations were tested in the Culex NxT “Rat Turn” Model. Studies consisted of 7
mg/kg doses of SaliPhe in 2% P407, SaliPhe in the F22 emulsion formulation, and
OM510 in 2% P407.
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2% P407 and F22 Emulsion SaliPhe Formulation Rat PK Studies
The pharmacokinetic (PK) studies were conducted on SaliPhe in its polymer and
emulsion formulations. Samples were pulled at 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours.
Eight mice were dosed at 7 mg/kg with on average approximately 500 μL 3.5 mg/mL
SaliPhe in P407 (4 Rats) or 550 μL 3.0 mg/mL SaliPhe in the F22 emulsion formulation
(4 Rats).

Both formulations showed rapid disposition with approximately 1 μg/mL

remaining in the blood after 15 minutes. PK parameters are shown below:

Table 5.5. Rat pharmacokinetic parameters for 7mg/kg Saliphenylhalamide in 2% P407 and F22
emulsion formulations.

C initial is initial concentration, AUC∞ is area under the curve

extrapolated to infinity, Vd is volume of distribution, and CL is clearance. P-values were
determined with student’s T-test with n=4.

As can be seen, insignificant changes (p=0.103) in the initial blood concentration
were seen between the two formulations. However, the P407 formulation appears to be

157
quantitatively higher, where the values are most likely not statistically significant due to
high variability within the sample size.

The P407 formulation did demonstrate a

statistically significant higher AUC than the F22 formulation. This may be explained by
the higher clearance and lower half-life of the F22 formulation. It is possible that due to
the small size of the micelles that they are rapidly cleared before the drug can diffuse into
the blood and eventually into the tissues. Therefore, we suggest that the 2% P407
formulation is likely to be the more likely translatable as it appears to have better
solubilization through transient binding allowing disposition before clearance. Individual
PK plots are shown below as well as average PK plots over the first four hours as blood
levels had reduced by over 99% within this time.
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Figure 5.12. Concentration vs. time plots of 4 rats injected with 7mg/kg
Saliphenylhalamide in 2% P407.
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Figure 5.13. Average first four hours for concentration vs. time plots of 4 rats injected
with 7mg/kg Saliphenylhalamide in 2% P407. Error bars are 1 standard deviation.
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Figure 5.14. Concentration vs. time plots of 4 rats injected with 7mg/kg
Saliphenylhalamide in F22 emulsion formulation.
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Figure 5.15. Average first four hours for concentration vs. time plots of 4 rats injected
with 7mg/kg Saliphenylhalamide in F22 emulsion formulation. Error bars are 1 standard
deviation.

2% P407 OM510 Formulation Rat PK Study
Due to time constraints, OM510 was tested only with the more favorable
formulation of 2% P407. Again, studies were conducted in 4 mice with a 7 mg/kg
SaliPhe dose (weight adjusted to account for increased molecular weight of prodrug).
However, only a limited number of samples were allowed due to a restricted timeline.
Therefore samples were only pulled at 0.25, 0.5, 1, and 2 hours. Unfortunately, two
hours did not allow for complete PK analysis as it appears a mixture of disposition,
metabolism of OMM 510 to SaliPhe, and additional clearance is still occurring in the rats.
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In order to attempt to pull any useful data, the average SaliPhe PK plot was used. These
PK parameters are shown below:

Table 5.6. Rat pharmacokinetic parameters for 7mg/kg OM510 in 2% P407 formulation. C
initial is initial concentration, AUC0→2hr is area under the curve for 0 to 2 hour time interval, Vd
is volume of distribution, and CL is clearance. Average is for n=4 rats.

While it is difficult to assess the actual parameters for comparison, a number of
testable observations can be made that will enable further interpretation. First, it appears
that OM510 provides a higher initial SaliPhe concentration upon conversion of the
prodrug, suggesting that it may slightly reduce disposition into the tissues. In addition,
OM510 gives a much higher AUC through the first four hours than seen with SaliPhe
over 24 hours.

This may be due to reduced clearance, reduced disposition, or a

combination of the two. Finally, the results give a half-life of approximately 1 hour,
which is significantly lower than that seen with SaliPhe in 2% P407. However, it is
speculated that disposition is still occurring and that the terminal phase, in which half-life
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is better measured, has not yet been reached at 2 hours. Individual and average PK plots
are shown below.
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Figure 5.16. Concentration vs. time plots of 4 rats injected with 7mg/kg OM510 in 2%
P407 formulation.
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Figure 5.17. Average concentration vs. time plots of 4 rats injected with 7mg/kg OM510
in 2% P407. Error bars are 1 standard deviation.

In summary, the OMM 510 analogue may offer superior PK parameters and have
an enhanced chance for translation into the clinic comparative to SaliPhe. Further
research is required, but the development of additional prodrugs also may offer
considerable promise for development.

In Vivo Murine Biodistribution Studies
Several attempts were made to recover and quantitate the levels of SaliPhe in the
tissue samples that were provided to us for the biodistribution study.

All sample

preparation methods were optimized to provide the highest yield and the same
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bioanalytical LC-MS/MS method used to analyze the PK samples above were utilized.
However, we were unable to determine SaliPhe levels above the limit of detection in the
study. Upon reflection and discussion, it was concluded that a future biodistribution
study will require using a two-week dosing regimen versus the single dose study that was
performed here. Based on the promising results with the OM510, we would recommend
planning to perform the biodistribution study on this analogue versus SaliPhe in the
future. It appears that OM510 may be superior from a PK standpoint.

5.4.

Conclusions
The growing number of viral outbreaks around the globe and threat of

weaponization of some of these viruses has lead to an uptick in the investigation of
prospective antiviral therapeutics.

Due to its utilization in viral replication, the V-

ATPase represents a potential endogenous protein for antiviral drug targeting. Previous
studies have shown SaliPhe to be a potent inhibitor of the V-ATPase, however, these
studies were done with little knowledge of the physicochemical properties in nonpharmaceutically relevant formulations.5-7,25-27 Therefore, here we looked to characterize
SaliPhe and formulate around its potential druggability concerns.
After initial solid-state characterization, main druggability concerns focused on
lack of solubility and acid liability. SaliPhe was shown to have an equilibrium aqueous
solubility of less than 10 μg/mL with a predicted solubility need of 3.5 mg/mL. In
addition, SaliPhe has a projected half-life in acid of less than two hours, which in
combination of poor predicted GI permeation made oral dosing unviable at this time.
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Therefore, solubility-enabling 2% P407 and F22 emulsion parenteral formulations were
created to overcome these concerns. These formulations were then subjected to in vitro
and in vivo screens to determine their effectiveness.
In vitro cell permeation screens showed poor permeability of both unformulated
and formulated SaliPhe into the brain; however, HUVEC permeability suggested
moderate permeation into the periphery. In vivo murine biodistribution studies were
conducted to confirm in vitro predictions, but tissue concentrations were below detectable
limits.

Therefore, pharmacokinetic studies were conducted to determine relevant

pharmacokinetic parameters. Here, the 2% P407 formulation appeared to be the more
druggable formulation with higher initial concentrations, AUC, volume of distribution,
and a longer half-life.
Finally, OM510, a proprietary prodrug of SaliPhe, was formulated and assessed
in in vitro and in vivo screens. OM510 was synthesized to promote increased solubility
and brain permeation. Due to material and time concerns, characterization was not
performed. Initial in vitro permeability screens suggested that OM510 is much more
permeable than the parent compound therefore it was moved into in vivo rat
pharmacokinetic studies.

OM510 was dosed in the 2% P407 formulation as this

formulation was more successful for the parent compound. Murine pharmacokinetic
studies supported in vitro studies suggesting that with a higher initial concentration,
AUC, and volume of distribution OM510 may be a more druggable compound than the
parent, Saliphenylhalamide.
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